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Summary 
 
The present work reports the outcome of the GIMEMA CML WP study CML0811, 
an independent trial investigating nilotinib as front-line treatment in chronic phase 
chronic myeloid leukemia (CML). Moreover, the results of the proteomic analysis 
of the CD34+ cells collected at CML diagnosis, compared to the counterpart from 
healthy donors, are reported. 
Nilotinib has been approved as front-line of CML based on the results of the 
Company-sponsored ENESTnd trial, where nilotinib showed a superior efficacy 
compared to imatinib. However, cardiovascular thrombotic events have been 
recently uncovered, rising concerns on the long-term safety profile of nilotinib. 
The treatment-free remission is considered one of the most important goals in 
CML, and a sustained deep molecular response (DMR, MR 4.0 or better) is a 
pre-requisite for treatment discontinuation. To date, very few data on the stability 
of the DMR with nilotinib are currently available. Even when treatment is stopped 
during a stable DMR, about half of the patients eventually relapse due to the 
persistence of leukemic stem cells resistant to therapy. 
Based on these considerations, it is extremely relevant to:  a) assess in an 
independent study the efficacy, including the stability of the molecular response, 
and the safety, with particular attention to the cardiovascular events, of nilotinib 
front-line; b) characterize the leukemic stem cells, understanding their differences 
with the normal counterpart. 
One hundred thirty CML patients in early chronic phase have been enrolled in 32 
Italian hematologic centers, with a median age at diagnosis of 50 years (range 
18-85). After a median follow-up of 24 months all patients are still alive, and only 
2 patients progressed to accelerated/blast phase (AP/BP). At the last contact, 
107/130 (82%) patients were still on treatment with nilotinib. The main reasons 
for treatment discontinuation were toxicity in 11 patients (8%), and failures in 5 
(4%) patients. Six patients (5%) had a cardiovascular event, including myocardial 
infarction and arterial thrombosis. Both LDL and HDL cholesterol fractions 
significantly increased during treatment. The optimal responders at 3, 6, and 12 
months according to ELN 2013 recommendations were 82.3%, 80%, and 53%, 
respectively; failures at the same time points were 10.7%, 3.8%, and 2.3%, 
respectively. The estimated 24 months cumulative rates of MR 4.0 and MR 4.5 
were 47% and 22%, respectively. Overall, 27/57 (47%, or 21% of the total) 
patients had a sustained MR 4.0; 6/30 (20%, or 5% of the total) patients had a 
sustained MR 4.5. The estimated 24-month overall-survival, progression-free 
survival, failure-free survival, and event-free survival were 100%, 98%, 94%, and 
73%, respectively. 
The proteomic analysis showed that the CD34+ cells from CML patients at 
diagnosis, compared to a normal counterpart, have: a lower phosphorylation of 
STAT2, STAT5, and of tyrosine kinases of the Src family (Lck, Fyn, Lyn, and 
Yes); a lower expression of the catalase, and a higher expression of FADD, 
HSP60 and HSP70. Taken together, these data show that CML CD34+ cells 
have a proteomic profile that promotes the quiescence through the inhibition of 
proliferation, and that favors cell survival despite cytotoxic stimuli. These 
characteristics may explain, at least partially, why these cells are resistant to the 
treatment with TKIs, which is highly effective in targeting more differentiated and 
proliferating cells.  
In conclusion, our study confirmed that nilotinib is highly effective in the 
prevention of the progression to AP/BP, a condition that today is still associated 
with high mortality rates. Despite the relatively short follow-up, cardiovascular 
issues, particularly atherosclerotic adverse events (AE), have emerged, and the 
frequency of these AEs may counterbalance the anti-leukemic efficacy. The deep 
molecular response rates in our study compare favorably to those obtained with 
imatinib, in historic cohorts, and confirm the findings of the Company-sponsored 
ENESTnd study164. Considering the increasing rates of deep MR over time, a 
significant proportion of patients will be candidate to treatment discontinuation in 
the next years, with higher probability of remaining disease-free in the long term. 
However, the presence of the additional and complex changes we found at the 
proteomic level in CML CD34+ cells should be taken into account for the 
investigation on novel targeted therapies, aimed at the eradication of the disease. 
1. Background and introduction  
 
1.1. Chronic Myeloid Leukemia: natural history and treatment results.  
 
Chronic Myeloid Leukemia (CML) is a hematopoietic stem cell disorder 
associated with a specific chromosomal translocation known as the Philadelphia 
(Ph) chromosome1. The molecular consequence of the translocation is the fusion 
of the Abl proto-oncogene to the Bcr gene, resulting in the production of a 
constitutively activated form of the ABL protein-tyrosine kinase2,3, whose activity 
gives growth advantage to leukemic cells, increases proliferation and cytokine-
independent growth, inhibits apoptosis, and alters adhesion pathways4-6. 
Expression of the BCR-ABL protein is able to induce leukemia in mice7,8. 
Clinically, CML progresses through three distinct phases of increasing 
refractoriness to therapy: chronic phase (CP, median duration without TKI 
therapy 3 to 4 years), accelerated phase (AP, median survival 8 to 18 months), 
and blast phase (BP, median survival 3 to 6 months)1. Most patients present in 
the chronic phase, which is characterized by splenomegaly and leukocytosis 
with, generally, few symptoms.  
CML can be effectively treated with imatinib (Glivec, Novartis Pharma): after 6-
year follow-up, the International Randomized Study of Interferon vs STI571 
(IRIS) showed a cumulative complete cytogenetic response (CCgR) rate of 82%9; 
however, after 8 years, only 56% of the patients were still on imatinib treatment10. 
Moreover, not all patients achieve an optimal response11 and about 10% of 
patients of patients loose the previously obtained response, particularly within the 
first three years of treatment9. For these patients second- and third-generations 
TKIs have been developed: nilotinib and dasatinib have been approved for first 
and second line treatment; bosutinib, and ponatinib for second line treatment. 
1.2. Response Monitoring  
 
Alongside the development of targeted therapies, that allows more patients to 
achieve optimal responses, the diagnostic procedures have also been refined. 
The objectives of treatment of CML are the normalization of hematopoiesis 
(complete hematologic response - CHR), the elimination of the Ph+ cells from the 
bone marrow (complete cytogenetic response - CCgR), the reduction of the 
BCR-ABL transcript levels from samples of peripheral blood by a factor of at least 
three logs, compared to the standardized baseline (major molecular response - 
MMR, corresponding to a BCR-ABL/ABL ratio ≤ 0.1% International Scale), and 
four logs or more (deep molecular response – DMR: MR 4.0 or more)12-14. 
Assessing the molecular response by quantitatively measuring the BCR-ABL 
transcripts, using real-time reverse transcriptase polymerase chain reaction (RQ-
PCR), is an established parameter of response that can be easily assessed from 
peripheral blood. Patients achieving a CCgR and a MMR have a better prognosis 
than patients achieving a CCgR alone15. Standardized molecular monitoring has 
become widely available in Europe through the efforts of EUTOS cooperation16 
and, in Italy, through the cooperative efforts of a group of laboratories nationwide 
which agreed to harmonize their activity and to share results of the molecular 
monitoring, managed within the frame of the Labnet network. These efforts led to 
the generation of comparable data on the residual disease. 
The response to TKI treatment is the most important prognostic factor. For this 
reason, the European Leukemia Net, since 200617, has provided 
recommendations that define the response to first-line treatment with any TKI. 
The updated definitions (ELN 2013) are reported in Table 118. 
 
 
 
 
 
 
 
 
 
 
 
Table. 1. 2013 ELN definition of response to front-line treatment with TKIs 
 
 
 
 
1.3. Nilotinib  
 
1.3.1. Introduction  
Nilotinib (Tasigna, AMN107, Novartis Pharma) is an aminopyrimidine derivative, 
available as an oral formulation: it is a rationally designed second-generation 
tyrosine kinase inhibitor with improved target specificity over imatinib. The ATP-
competitive inhibition of the BCR-ABL protein tyrosine kinase activity prevents 
the activation of BCR-ABL dependent mitogenic and anti-apoptotic pathways 
(e.g., PI3 kinase and STAT5). Following the administration to animals, nilotinib is 
moderately absorbed (approximately 30% bioavailability) and well tolerated. The 
effects of a systemic exposure (Cmax, AUC) over the range of 50 to 1200 mg 
once daily have been assessed in patients with imatinib-resistant CML in chronic, 
accelerated or blast phase, relapsed or refractory Ph+ acute lymphoblastic 
that any one of the 3 risk scores is superior or more convenient, and there is no
clear evidence that intermediate-risk patients behave differently from low-risk
ones. Therefore, regardless of which system is used, we recommend dividing
patients into low- (including intermediate) and high-risk populations. Chro-
mosome 9 deletions and variant translocations have no value for prognosis,81-83
whereas CCA/Ph1 have been reported to have an adverse prognostic value,
particularly in the case of the so-called “major route” abnormalities, includ-
ing trisomy 8, trisomy Ph (1der(22)t(9;22)(q34;q11)), isochromosome 17
(i(17)(q10)), trisomy 19, and ider(22)(q10)t(9;22)(q34;q11).83,84 High-risk
and major route CCA/Ph1 can help identify patients eligible for inves-
tigational approaches, but in daily practice they do not mandate different
initial treatments. Major route CCA/Ph1 developing during treatment were
conﬁrmed to be a signal of acceleration.4,5,42,78,79,85
Many other baseline factors, including the gene expression proﬁles, spe-
ciﬁc polymorphisms of genes coding for TKI transmembrane transporters or
TKI-mediated apoptosis, and the detailed molecular dissection of the genome,
have been reported to have prognostic implications, but these data are not yet
sufﬁciently mature to use for planning treatment.4,5,42,86-92
Response to treatment
The response to TKI is the most important prognostic factor. In the
previous versions of the ELN recommendations the response to ﬁrst-
line treatment was limited to imatinib. Now that there are more
TKIs, we do not recommend which TKI should be used but which
response should be achieved, irrespective of the TKI that is used.
The responses are deﬁned as “optimal” or “failure” (Table 5).
Optimal response is associated with the best long-term outcome—that
is, with a duration of life comparable with that of the general
population, indicating that there is no indication for a change in that
treatment. Failure means that the patient should receive a different
treatment to limit the risk of progression and death. Between optimal
and failure, there is an intermediate zone, which was previously
referred to as “suboptimal” and is now designated as “warning.”
Warning implies that the characteristics of the disease and the
response to treatment require more frequent monitoring to permit
timely changes in therapy in case of treatment failure.
In the deﬁnition of response, a controversial point is the value of
early molecular response, particularly after 3 months of treatment. A
BCR-ABL1 transcripts level .10% was reported to be prognostically
signiﬁcant in several studies.93-103 However, the conclusion of the
panel is that a single measurement of BCR-ABL transcripts level is not
sufﬁcient to deﬁne as failure necessitating a change of treatment,
whereas 2 tests (at 3 and 6months) and supplementary tests in between
provide more support for the decision to change the treatment. Failures
must be distinguished as either primary (failure to achieve a given
response at a given time) or secondary (loss of response) (Table 5).
The deﬁnitions of the response to second-line treatment, based on
the same concepts, are shown in Table 6. They are limited to dasatinib
and nilotinib,5,42-46,69,77,104-109 but until more data become available,
they may provisionally serve also for the other TKIs. These deﬁ-
nitions have profound therapeutic implications because they mark the
difﬁcult and critical boundaries between TKIs and alloSCT.
Treatment recommendations
It is recommended that in practice outside of clinical trials, the ﬁrst-
line treatment of CP CML can be any of the 3 TKIs that have been
approved for this indication and are available nearly worldwide,
namely imatinib (400mg once daily), nilotinib (300mg twice daily),
and dasatinib (100 mg once daily). These 3 TKIs can also be used in
second or subsequent lines, at the standard or at a higher dose (400
mg twice daily for imatinib, 400 mg twice daily for nilotinib, and
70 mg twice daily or 140 mg once daily for dasatinib). Bosutinib
(500 mg once daily) has been approved by the FDA and EMA for
patients resistant or intolerant to prior therapy. Ponatinib (45 mg
once daily) has also been approved by the FDA for patients
resistant or intolerant to prior TKI therapy. Also approved, for
patients in whom prior TKI therapy fails, are radotinib, which is
available in Korea,110 and omacetaxine, which is a non-TKI drug
approved by the US FDA.111,112
Busulfan is not recommended. Hydroxyurea can be used for
a short time before initiating a TKI, until the diagnosis of CML has
been conﬁrmed. rIFNɑ alone is recommended only in the rare
circumstances in which a TKI cannot be used. The combinations of
TKIs and rIFNɑ are potentially useful but still investigational.113
Cytotoxic chemotherapy is never recommended in CP but may be
useful to control BP and to prepare BP patients for alloSCT.
Treatment recommendations for CP are proposed in Table 7.
These recommendations are based on a critical evaluation of efﬁcacy,
but it is acknowledged and recommended that the choice of the TKI
must take into account tolerability and safety, as well as patient
characteristics, particularly age and comorbidities, which may be
predictive of particular toxicities with the different TKIs. In all cases
of “warning,” research and investigational studies are warranted and
should be encouraged to improve treatment results.
Table 5. Definition of the response to TKIs (any TKI) as first-line
treatment
Optimal Warning Failure
Baseline NA High risk
Or
CCA/Ph1, major
route
NA
3 mo BCR-ABL1 #10%
and/or
Ph1 #35%
BCR-ABL1 .10%
and/or
Ph1 36-95%
Non-CHR
and/or
Ph1 .95%
6 mo BCR-ABL1 ,1%
and/or
Ph1 0
BCR-ABL1 1-10%
and/or
Ph1 1-35%
BCR-ABL1 .10%
and/or
Ph1 .35%
12 mo BCR-ABL1 #0.1% BCR-ABL1 .0.1-1% BCR-ABL1 .1%
and/or
Ph1 .0
Then, and
at any time
BCR-ABL1 #0.1% CCA/Ph– (–7, or 7q–) Loss of CHR
Loss of CCyR
Confirmed loss of
MMR*
Mutations
CCA/Ph1
The definitions are the same for patients in CP, AP, and BP and apply also to
second-line treatment, when first-line treatment was changed for intolerance. The
response can be assessed with either a molecular or a cytogenetic test, but both are
recommended whenever possible. Cutoff values have been used to define the
boundaries between optimal and warning, and between warning and failures.
Because cutoff values are subjected to fluctuations, in case of cytogenetic or molecular
data close to the indicated values, a repetition of the tests is recommended. After 12
months, if an MMR is achieved, the response can be assessed by real quantitative
polymerase chain reaction (RQ-PCR) every 3 to 6 months, and cytogenetics is
required only in case of failure or if standardized molecular testing is not available.
Note that MMR (MR3.0 or better) is optimal for survival but that a deeper response
is likely to be required for a successful discontinuation of treatment.
NA, not applicable; MMR, BCR-ABL1 #0.1% 5 MR3.0 or better; CCA/Ph1,
clonal chromosome abnormalities in Ph1 cells; CCA/Ph–, clonal chromosome
abnormalities in Ph– cells.
*In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level $1%.
876 BACCARANI et al BLOOD, 8 AUGUST 2013 x VOLUME 122, NUMBER 6
For personal use only.on December 13, 2014. by guest  www.bloodjournal.orgFrom 
leukemia (ALL), or other hematologic malignancies19. With once daily (QD) 
dosing, the steady-state, the Cmax, and the AUC increased with increasing dose 
from 50 mg to 400 mg/day in a generally dose-proportional manner, but 
appeared to plateau at dose levels of 400 mg/day or higher, remaining relatively 
constant over the dose range from 400 mg to 1200 mg. QD doses of nilotinib 400 
mg or 800 mg showed no appreciable differences in serum exposure to drug. 
Using a twice daily schedule (BID), the dose-limiting exposure has been partially 
overcame, with a daily steady-state serum nilotinib exposure at a dose of 400 mg 
BID being approximately 35% greater than with a dose of 800 mg once daily. 
However, there was no further relevant increase in nilotinib exposure observed 
with the administration of the 600 mg BID dose (1200 mg/day). With multiple oral 
doses of nilotinib, steady-state conditions were achieved by day 8 after initiating 
nilotinib treatment. The median time to reach Cmax of nilotinib (tmax) was 3 hours. 
Drug half-life averaged 17 hours for once daily dosing. CYP3A4 appears to be 
the major enzyme responsible for the metabolism of nilotinib under in vivo 
conditions whereas the contribution of CYP2C8 is expected to be minor (~8%). 
Nilotinib also seems to inhibit CYP2C8, CYP2C9, CYP2D6, CYP3A4/5, and 
UGTIA1 activity in clinical settings. 
 
1.3.2. Clinical studies  
The efficacy and safety of nilotinib in the treatment of patients who are resistant 
to or intolerant of imatinib led to its further evaluation in the treatment of newly 
diagnosed CML20-22.  
Data from two Investigator-initiated (GIMEMA and MDACC) trials demonstrate 
high rates of cytogenetic and molecular responses in patients with newly 
diagnosed CML23,24: the 12-months complete molecular response rates were 7% 
in the GIMEMA trial and 10 % in the MDACC trial. A phase 3 randomized study 
comparing the efficacy and safety of 300 or 400 mg bid nilotinib with imatinib 400 
mg daily in patients with newly diagnosed Ph+ CP-CML (ENESTnd) is actually 
ongoing25. This study showed a superiority of nilotinib 300 mg or 400 mg BID 
over imatinib: CCgR rates at 12 months were 80%, 78% and 65%, respectively; 
MMR rates at 12 months were 44%, 43% and 22%, respectively. The 
progression to advanced disease was lower for nilotinib 300 mg bid (2 pts) and 
nilotinib 400 mg bid (1 pt) compared with imatinib 400 mg (11 pts).  
The best cumulative MMR rates at 24 months26 were 62%, 59% and 37%, for 
nilotinib 300 mg BID, nilotinib 400 mg BID, and imatinib 400 mg OAD 
respectively.  Recently, the ENESTnd trial has been updated27: for nilotinib 300 
mg BID, nilotinib 400 mg BID, and imatinib 400 mg OAD, MMR rates by 60 
months were 77%, 77% and 60% (p < 0.001), respectively; and MR 4.5 rates by 
60 months were 54%, 53% and 31% (p < 0.001), respectively. By the 60-month 
data cut-off date, 17 patients progressed to AP/BC on core treatment, 12 in the 
imatinib arm, 2 in the nilotinib 300 mg BID arm and 3 in the nilotinib 400 mg BID 
arm. No additional patients with progression to AP/BC were observed on core 
treatment in any treatment arm since the 24-month analysis.  
Nilotinib 300 mg BID has been shown to be equally effective and better tolerated 
than 400 mg BID. Novartis Pharma has submitted regulatory applications 
worldwide, obtaining the registration for the first-line indication in USA, EU and 
Japan. 
 
1.3.3. Toxicity profile 
1.3.3.1. Adverse events 
The most frequently reported drug-related adverse events (AEs) in CML-AP and 
CML-CP patients who are resistant to or intolerant of imatinib are shown in Table 
1. At 24 months follow-up, almost all CML patients experienced AEs during the 
course of the study. In CML-CP patients, the most frequent SAEs were 
thrombocytopenia (3.4%), neutropenia (2.2%), angina pectoris (2.8%) and 
pyrexia (2.5%). In CML-AP patients, the most frequent SAEs were 
thrombocytopenia (8.0%), neutropenia (5.8%), pneumonia (5.1%), and pyrexia 
(4.4%). The rate of discontinuations due to AEs, regardless of relationship to 
study medication, was similar for both stages of the disease (19.0% of CML-CP 
patients and 17.5% of CML-AP patients). For CML-CP, the incidence of AEs 
leading to discontinuation was low; the most frequent AEs associated with 
discontinuation were neutropenia and thrombocytopenia, which occurred in 10 
(3.1%) patients each. For CML-AP, the incidence of AEs leading to 
discontinuation was low; the most frequent AE associated with discontinuation 
was thrombocytopenia, which occurred in 10 (7.3%) patients. 
 
Table 2.  Most frequent drug-related adverse events (more than 5%) at 
24-months in CML-AP and -CP patients (Study 2101 E1 and E2) 
 
 All grades CML-AP,  
N=137, n (%) 
All grades CML-CP,  
N=321, n (%) 
Any event 120 (87.6) 304 (94.7) 
Thrombocytopenia 
Neutropenia 
Rash  
Anemia  
Pruritus  
Lipase increased  
Fatigue  
Constipation  
Diarrhea  
52 (38.0) 
31 (22.6) 
29 (21.2) 
24 (17.5) 
24 (17.5) 
18 (13.1) 
14 (10.2) 
13 (9.5) 
13 (9.5) 
90 (28.0) 
48 (15.0) 
99 (30.8) 
42 (13.1) 
84 (26.2) 
41 (12.8) 
65 (20.2) 
43 (13.4) 
39 (12.1) 
Leukopenia  
Muscle spasms  
Nausea  
Alopecia  
Myalgia  
Blood bilirubin increased  
Headache  
Hyperbilirubinemia  
13 (9.5) 
13 (9.5) 
13 (9.5) 
12 (8.8) 
12 (8.8) 
11 (8.0) 
11 (8.0) 
11 (8.0) 
13 (4.0) 
24 (7.5) 
79 (24.6) 
27 (8.4) 
33 (10.3) 
22 (6.9) 
57 (17.8) 
23 (7.2) 
Abdominal pain  
Pyrexia  
10 (7.3) 
9 (6.6) 
17 (5.3) 
13 (4.0) 
Anorexia   
Pain in extremity  
Arthralgia  
Hypophosphataemia  
Peripheral edema  
Vomiting  
8 (5.8) 
8 (5.8) 
7 (5.1) 
7 (5.1) 
7 (5.1) 
5 (3.6) 
23 (7.2) 
17 (5.3) 
24 (7.5) 
8 (2.5) 
20 (6.2) 
41 (12.8) 
Alanine aminotransferase increase  
Bone pain 
Erythema  
Asthenia  
Aspartate aminotransferase 
increase 
Dry skin   
Dyspnea  
5 (3.6) 
5 (3.6) 
2 (1.5) 
5 (3.6) 
4 (2.9) 
5 (3.6) 
0 (0.0) 
3 (2.2) 
34 (10.6) 
24 (7.5) 
23 (7.2) 
21 (6.5) 
20 (6.2) 
20 (6.2) 
17 (5.3) 
17 (5.3) 
AE = adverse event, AP = accelerated phase, CML = chronic myeloid leukemia, CP = chronic phase, 
1The source used for 24-month 2101E1 data (cut-off 29-Aug-2008) and 24-month 2101E2 data (cut-off 20-
Apr- 
2008 
Source: [CAMN107A2101E1] and [CAMN107A2101E2 CSR]. 
 Furthermore, a subgroup analysis evaluated the occurrence of cross-intolerance 
to nilotinib in imatinib-intolerant patients with CML- CP or AP (n=122; CP:95 
AP:27). Only 4/75 (5%) patients with non-hematologic imatinib-intolerance 
experienced similar grade 3/4 AE on nilotinib. Only 7/40 (18%) patients with 
hematologic toxicity on imatinib discontinued nilotinib for the same reason (all 
due to grade 3/4 thrombocytopenia). 
The frequency and the degree of non-hematologic AEs in the 5-years update of 
the first line treatment trial ENESTnd are reported in Table 2. 
 
Table 3. Most frequently reported study drug-related non-hematologic 
adverse events (at least 5% in any treatment group) by preferred term 
(Safety set) - ENESTnd 
 
 All grades CTC grade 3 or 4 
Preferred term 
Imatinib 
400 mg 
QD 
N=280 
n (%) 
Nilotinib 
300 mg 
BID 
N=279 
n (%) 
Nilotinib 
400 mg 
BID 
N=277 
n (%) 
Imatinib 
400 mg 
QD 
N=280 
n (%) 
Nilotinib 
300 mg 
BID 
N=279 
n (%) 
Nilotinib 
400 mg 
BID 
N=277 
n (%) 
ANY AE 264 (94.3) 257 (92.1) 269 (97.1) 125 (44.6) 120 (43.0) 158 (57.0) 
Rash 39 (13.9) 93 (33.3) 109 (39.4) 5 (1.8) 2 (0.7) 7 (2.5) 
ALT Increased 17 (6.1) 67 (24.0) 81 (29.2) 6 (2.1) 13 (4.7) 16 (5.8) 
Headache 29 (10.4) 46 (16.5) 62 (22.4) 1 (0.4) 5 (1.8) 3 (1.1) 
Nausea 97 (34.6) 39 (14.0) 58 (20.9) 1 (0.4) 2 (0.7) 3 (1.1) 
Hyper-bilirubinaemia 4 (1.4) 46 (16.5) 47 (17.0) 0 8 (2.9) 10 (3.6) 
Pruritus 15 (5.4) 49 (17.6) 43 (15.5) 0 1 (0.4) 1 (0.4) 
AST increased 14 (5.0) 34 (12.2) 42 (15.2) 4 (1.4) 5 (1.8) 5 (1.8) 
Hypophosphataemia 38 (13.6) 35 (12.5) 41 (14.8) 13 (4.6) 6 (2.2) 16 (5.8) 
Alopecia 16 (5.7) 29 (10.4) 38 (13.7) 0 0 0 
Dry skin 13 (4.6) 27 (9.7) 32 (11.6) 0 0 0 
Myalgia 35 (12.5) 29 (10.4) 32 (11.6) 1 (0.4) 2 (0.7) 2 (0.7) 
Fatigue 37 (13.2) 34 (12.2) 30 (10.8) 4 (1.4) 0 2 (0.7) 
Arthralgia 23 (8.2) 23 (8.2) 28 (10.1) 1 (0.4) 1 (0.4) 0 
Lipase increased 10 (3.6) 30 (10.8) 28 (10.1) 7 (2.5) 23 (8.2) 20 (7.2) 
Vomiting 52 (18.6) 16 (5.7) 25 (9.0) 0 0 3 (1.1) 
 
1.3.3.2. Lipid and glucose elevations 
 
Lipid and glucose elevation represent important adverse events that have been 
associated with nilotinib treatment, and with potential important implications on 
the overall cardiovascular risk. In the ENESTnd Study25, considering all the 
observed adverse events (not only drug-related events) the proportion of patients 
with high cholesterol (almost all grade 1 or 2) was greater in the nilotinib treated 
patients compared to the imatinib ones (27.6% and 26.7% in the nilotinib 300 mg 
BID and 400 mg BID groups, versus 3.9% in the imatinib group). Also the 
proportion of patients with post-baseline LDL values >100 mg/dL was higher in 
the nilotinib 400 mg BID group (43.3%) and the nilotinib 300 mg BID group 
(38.4%) as compared to imatinib group (18.6%). Triglyceride abnormalities were 
slightly more frequent in the nilotinib treated patients compared to the imatinib 
ones (11.8% and 10.5% in the nilotinib 300 mg and 400 mg groups, vs. 7.9% in 
the imatinib group). 
Abdominal pain 22 (7.9) 28 (10.0) 24 (8.7) 2 (0.7) 3 (1.1) 0 
Muscle spasms 83 (29.6) 25 (9.0) 24 (8.7) 3 (1.1) 0 2 (0.7) 
Diarrhoea 86 (30.7) 24 (8.6) 20 (7.2) 9 (3.2) 1 (0.4) 0 
Amylase increased 9 (3.2) 18 (6.5) 19 (6.9) 3 (1.1) 2 (0.7) 2 (0.7) 
Constipation 7 (2.5) 27 (9.7) 19 (6.9) 0 0 1 (0.4) 
Oedema peripheral 49 (17.5) 15 (5.4) 19 (6.9) 0 1 (0.4) 0 
Erythema 9 (3.2) 7 (2.5) 17 (6.1) 0 0 0 
Abdominal pain 11 (3.9) 17 (6.1) 16 (5.8) 0 0 2 (0.7) 
Hypercholesterolaemia 0 9 (3.2) 16 (5.8) 0 1 (0.4) 0 
Asthenia 24 (8.6) 26 (9.3) 15 (5.4) 0 1 (0.4) 2 (0.7) 
Dyspepsia 16 (5.7) 13 (4.7) 15 (5.4) 0 0 1 (0.4) 
Hyperglycaemia 2 (0.7) 12 (4.3) 15 (5.4) 0 2 (0.7) 4 (1.4) 
Blood ALP increased 7 (2.5) 6 (2.2) 14 (5.1) 1 (0.4) 0 0 
Bone pain 10 (3.6) 11 (3.9) 14 (5.1) 1 (0.4) 0 1 (0.4) 
Pain in extremity 23 (8.2) 13 (4.7) 9 (3.2) 1 (0.4) 1 (0.4) 2 (0.7) 
Face oedema 37 (13.2) 1 (0.4) 6 (2.2) 1 (0.4) 0 0 
Eyelid oedema 50 (17.9) 2 (0.7) 5 (1.8) 1 (0.4) 0 1 (0.4) 
Weight increased 18 (6.4) 8 (2.9) 4 (1.4) 2 (0.7) 3 (1.1) 0 
Periorbital oedema 40 (14.3) 1 (0.4) 3 (1.1) 0 0 0 
Elevated glucose values were more frequent in the nilotinib treated patients than 
in the imatinib ones. The proportion of patients with grade 3/4 increased serum 
glucose was higher in the nilotinib groups (7.2%; 20 patients in the nilotinib 300 
mg BID and 6.9%; 19 patients in the nilotinib 400 mg BID), while grade 3/4 
glucose increase was reported only in one patient (0.4%) in the imatinib group. 
The proportion of patients with glycosylated hemoglobin >5.7% at any time in the 
study was higher in the nilotinib 400 mg BID arm (24.2%) and nilotinib 300 mg 
BID arm (21.9%) as compared to the imatinib arm (18.2%). Also the proportion of 
patients with glycosylated hemoglobin ≥6.5% was higher in the nilotinib 300 mg 
BID group (11.8%) and the nilotinib 400 mg BID group (11.6%) as compared to 
imatinib group (3.6%). 
 
1.3.3.3. Ischemic vascular or ischemic cardiovascular events 
 
Peripheral ischemic vascular adverse events have been reported with unusual 
incidence in nilotinib treated patients28,29; the underlying mechanisms are object 
of active investigations.  
In the ENESTnd Study, newly diagnosed or worsened Ischemic Vascular and 
Ischemic Cardiovascular Events such as Ischemic Heart Disease (IHD), Ischemic 
Cerebrovascular Event (ICVE) or Peripheral Artery Occlusive Disease (PAOD) 
have occurred in a relatively small number of CML-CP patients treated with 
nilotinib. However, such events have been reported with higher frequency in the 
nilotinib treatment arms compared with the imatinib treatment arm.  
Up to the data cut-off for the 60 Month analysis (30-Sep-2013)27, the number of 
patients reported with events is as follows: 
• Nilotinib 300mg BID: IHD, 11 (3.9%); ICVE, 4 (1.4%); PAOD, 7 (2.5%) 
• Nilotinib 400mg BID: IHD, 24 (8.7%); ICVE, 9 (3.2%); PAOD, 7 (2.5%) 
• Imatinib 400mg QD: IHD, 5 (1.8%); ICVE, 1 (0.4%); PAOD, 0 (0.0%) 
The majority of reported ischemic vascular and ischemic cardiovascular events 
were in patients with associated risks factors (e.g., advanced age, hypertension, 
hyperlipidemia, hypercholesterolemia, smoking, diabetes mellitus, pre-existing 
peripheral vascular disease). The background incidence of these events has not 
been established for the CML patient population. However, other studies 
reported an increased incidence of vascular events in nilotinib treated patients 
compared to imatinib ones30,31. 
Ischemic heart disease 
Ischemic heart disease (IHD) group included angina pectoris, coronary artery 
disease, acute myocardial infarction, coronary artery stenosis, myocardial 
infarction, myocardial ischaemia, angina unstable, blood creatin-phosphokinase 
MB increased, coronary artery occlusion, coronary artery restenosis, and 
troponin increased. AEs grouped under IHD were more frequent with nilotinib 
than with imatinib: there were 11 patients (3.9%) in the nilotinib 300 mg BID 
group and 24 patients (8.7%) in the nilotinib 400 mg BID group with IHD, 
compared to five patients (1.8%) in the imatinib group. Fourteen patients in the 
nilotinib 400 mg BID group and one patient in the nilotinib 300 mg BID group had 
AEs grouped under IHD that were considered study drug-related. Most of the 
IHD events were considered serious and were grade 3/4. Ten patients (3.6%) in 
the nilotinib 400 mg BID group discontinued study drug due to the events 
grouped under ischemic heart disease. The cumulative incidence of such events 
continue to increase over time: since the 48-month data cut-off, there were 12 
additional patients with IHD; two in the imatinib group with no suspected 
relationship to study treatment, and ten in the nilotinib 400 mg BID group, and 
five were considered nilotinib-related. 
Peripheral arterial occlusive disease 
Peripheral arterial occlusive disease (PAOD) group included peripheral arterial 
occlusive disease, peripheral artery stenosis, intermittent claudication, peripheral 
ischemia, and arterial occlusive disease.  
Since the beginning of the study there were 14 patients with reported PAOD: no 
patients in the imatinib group, seven patients (2.5%) each in the nilotinib 300 mg 
BID and 400 mg BID group. Serious PAOD events were reported for nine 
patients (four in the nilotinib 300 mg BID group and five patients in the nilotinib 
400 mg BID group). Seven patients (three in nilotinib 300 mg BID group and four 
in nilotinib 400 mg BID group) had study drug related peripheral arterial occlusive 
disease. One patient in nilotinib 300 mg BID group discontinued the study 
treatment due to PAOD and three patients in nilotinib 400 mg BID group 
discontinued the study drug due to peripheral artery stenosis and intermittent 
claudication. Since the 48-month data cut-off, there were five patients (three in 
the nilotinib 300 mg BID group and two in the nilotinib 400 mg BID group) with 
newly reported PAOD. 
Ischemic cerebrovascular events 
Ischemic cerebrovascular events group included cerebrovascular accident, 
ischemic stroke, transient ischemic attack, carotid artery stenosis, cerebral 
infarction, cerebral ischemia, amaurosis fugax, basilar artery stenosis, and 
cerebrovascular disorder. 
At the 60-month data cut-off, 14 patients were reported with AEs grouped under 
ischemic cerebrovascular events: one patient (0.4%) in the imatinib group, four 
patients (1.4%) in the nilotinib 300 mg BID group and nine patients (3.2%) in the 
nilotinib 400 mg BID group. The majority of patients (11 patients) were reported 
with AEs that were considered serious by investigators (one patient in imatinib 
group, four patients in nilotinib 300 mg BID group and six patients in nilotinib 400 
mg BID). Since the 48-month data cut-off, there were five additional patients with 
reported ischemic cerebrovascular events (one in the nilotinib 300 mg BID group 
and four in the nilotinib 400 mg BID group).  
1.4. Molecular pathways involved in CML 
 
Several molecular events are implicated in the disease, with BCR- ABL 
possessing the capacity to target a number of intermediary adapter molecules 
(including, GRB2, CBL and CRKL) that have been shown to be important in the 
activation of multiple signal transduction cascades facilitating unregulated 
proliferation and inappropriate survival of malignant cells32. Specifically, results 
from co-immunoprecipitation experiments observed the formation of stable 
complexes between BCR-ABL and several adapter proteins such as CRKL, 
SHC, CBL, p62DOC, and PI3-kinase33,34. In addition, tyrosine phosporylation of 
BCR-ABL at specific residues regulated the binding of other proteins such as 
GRB235. As a result, important pro-survival, proliferative and anti-apoptotic 
pathways are activated including RAS, STAT5, and Akt. Conversely, functional 
cooperation between these pathways is required to promote the full oncogenic 
activity of BCR-ABL36. 
 
Signal transducer and activator of transcription 5 (STAT5). The importance 
of the transcription factor STAT5 in chronic myeloid leukemia is well established. 
Over-expression of a constitutively active STAT5 protein in total bone marrow 
and long-term hematopoietic stem cells results in the induction of a CML-like 
condition comparable to the BCR-ABL induced disease37. Conversely, deletion of 
the Stat-5 gene locus prevented the development of myeloid or lymphoid 
leukemia in primary murine recipients of bone marrow transduced with a 
retrovirus encoding BCR-ABL38. Overall, STAT5 has been shown to have the 
capacity to mediate anti-apoptotic mechanisms and enhance cell viability via the 
up-regulation of genes such as BCL-XL and MCL1, in addition to stimulating cell 
proliferation39. The BCR-ABL oncoprotein is required in order to phosphorylate a 
critical tyrosine residue that regulates oligomerization of STAT5, and its 
subsequent nuclear translocation and DNA binding40,41. Interestingly, STAT5 has 
been implicated in the development of drug resistance to tyrosine kinase 
inhibitors (TKI; first-line CML therapy). Enhanced STAT5 expression has shown 
to result in the increased probability of acquiring BCR-ABL mutations, as well as 
contributing to a loss of responsiveness in prolonged disease42. Low expression 
levels of STAT5 correlate with increased sensitivity to treatment in vitro, while 
enhanced expression leads to a decreased therapeutic response43. Warsch and 
co-workers reported a highly significant association between the expression level 
of STAT5 mRNA and the occurrence of BCR-ABL mutations in a cohort of fifty 
CML patients, with the production of reactive oxygen species (ROS) mediating 
the effect42. The upregulation of STAT5 also has been shown to increase the 
number and rate of double-stranded breaks contributing to the enhanced 
mutation rate. 
 
Janus kinase 2 (Jak2). Evidence suggests that the STAT5/Jak pathway is 
involved in the signalling of more than fifty growth factors and cytokines, 
regulating various cellular events including proliferation, differentiation, apoptosis, 
survival, and migration44,45. In physiological conditions, Jak2 possesses a 
functional role in immune cell development and hematopoiesis. Activation of Jak2 
may also be observed in the initiation and maintenance of cancer, with the 
discovery of a single point mutation within the non-receptor tyrosine kinase Jak2 
(a substitution of a valine residue by phenylalanine at amino acid 617, resulting in 
Jak2V617F) responsible for facilitating the development of a subset of 
myeloproliferative disorders46. In addition, as the primary activator of STAT5, it is 
hypothesized that Jak2 is an essential component of BCR-ABL-driven 
leukemogenesis40. 
Activation of Jak2 via BCR-ABL phosphorylation, has been verified in several cell 
lines expressing different BCR-ABL variants, as well as in leukemic cells derived 
from CML patients47. Although inhibition of its kinase activity has been reported 
to induce apoptosis in BCR-ABL expressing leukemia cells, recent studies 
suggest that complete deletion of the Jak2 gene significantly accelerate disease 
development with increased white blood cell counts and severe splenomegaly 48. 
It has been proposed that as an important component of BCR-ABL signaling, 
Jak2 is important in the regulation of Ph+ cells through the capacity to mediate 
disease maintenance and progression49,50. Due to the conflicting literature 
however, further study is required in order to completely elucidate the role of 
Jak2 in CML as well as confirm its validity as a therapeutic target. 
 
Mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway is 
involved in the regulation of various cellular processes, including proliferation, 
differentiation, and survival51. Activation of MAPK signalling via Ras results in the 
nuclear translocation of extracellular signal regulated kinase (ERK) in order to 
effect gene expression. BCR-ABL has been determined to be a potent activator 
of Ras, with autophosphorylation of tyrosine 177 within the BCR first exon 
providing a docking site for the adapter molecule Grb-2, and subsequent 
stabilization of Ras in its active GTP-bound form35. Interestingly, activating 
mutations in Ras are rarely observed in Ph+ CML suggesting that BCR-ABL is 
required for the constitutive activation of Ras and therefore, the regulation of 
downstream mechanisms52. Mitogen-activated protein kinase kinase (MEK) is 
important in the phosphorylation of ERK, promoting cell proliferation53. Recently, 
the importance of a persistently high level of MEK-dependent negative feedback 
was published, with the ability to facilitate BCR-ABL-mediated oncogene 
addiction by regulating myeloid growth factor receptor (GF-R) signaling54. In 
addition, the anti-apoptotic factor Mcl-1 is also constitutively expressed via Ras 
activation in BCR-ABL-expressing cells enhancing survival55. A number of MAPK 
pathways have been implicated in the pathogenesis of Ph+ disease contributing 
to malignant transformation, including the main MAPK family members: ERK1/2, 
ERK5, c-Jun N- terminal kinase (JNK) and p38 MAPK. Extensive research 
involved in the determination of the cellular pathways involved in the 
pathogenesis of BCR-ABL+ CML has been conducted, with the activation of the 
ERK1/2 pathway important in disease development and progression. In 
embryonic stem cells transformed by BCR-ABL, ERK1/2 is constitutively 
activated56. Conversely, the oncogenic potential of BCR-ABL is enhanced by Ras 
via the activation of the ERK signaling cascade57. Important in cellular survival, 
activation of the ERK1/2 pathway is also thought to be important in the down-
regulation of the pro- apoptotic factor Bcl-2 interacting mediator of cell death 
(BIM) in both hematopoietic progenitor cells and BCR-ABL transformed murine 
bone marrow-derived Ba/F3 cells55. Furthermore, the ERK1/2 pathway has been 
implicated as a mediator in the BCR- ABL-induced activation of the transcription 
factor STAT3 in both primary CML progenitor cells and in murine embryonic stem 
cells58. Evidence suggests that ERK1/2 may also regulate BCR-ABL-mediated 
disruption of the translational-regulator heterogenous nuclear ribonucleoprotein K 
(hnRNP-K) which has been shown to have an important role in the development 
of blast phase CML59. Despite this, inhibition of ERK1/2 signaling alone failed to 
significantly induce cell death in BCR-ABL+ leukemic cells, indicating that these 
cells utilize multiple survival pathways60. Interestingly, a number of studies have 
implicated a paradoxical activation of the ERK1/2 pathway in TKI resistance 61. In 
the K562 cell line resistant to TKI treatment, imatinib effectively attenuated the 
phosphorylation of all MAPK signaling, except ERK1/262. Additionally, co-
incubation with an ERK1/2 inhibitor (U0126) resulted in reduced phospho-
ERK1/2 levels in resistant K562 cells, restoring sensitivity to TKI therapy. It thus 
proposed that activation of ERK1/2 may be independent of BCR-ABL in select 
cases of CML. 
Observed as a parallel MAPK pathway to ERK1/2, ERK5 has been recognized 
as a component of regulatory cell signaling, with the capacity to mediate the 
transcription of myocyte-specific enhancer factor 2C (MEF2C), an important 
factor in the differentiation of myeloid cells, influencing the cellular fate between 
monocyte and granulocyte63. Buschbeck and co-workers investigated the role of 
ERK5 in pro-survival signaling of BCR-ABL+ leukemia cells64. Results indicated 
that BCR-ABL tyrosine kinase activity may affect the ERK5 pathway by at least 
two independent mechanisms: (1) through the capacity to mediate ERK5 
activation and, (2) by increasing the protein level of ERK5. Subsequent 
experiments aimed to provide insight regarding the functional association 
between ERK5 and oncogenic BCR-ABL signaling, with the basal activity of 
ERK5 enhancing cellular transformation of Rat-1 fibroblasts and contributing to 
the cellular survival of the human megakaryoblastic leukemia cell line, MEG-01. 
Suppression of the p38 MAPK signaling pathway appears to contribute to BCR-
ABL leukemogenesis via the ability to mediate growth inhibitory and apoptotic 
mechanism in BCR-ABL+ cells65. Ectopic expression of BCR-ABL in embryonic 
stem cells was shown to attenuate p38 MAPK activation. Furthermore, studies 
indicate that BCR-ABL-mediated leukemic transformation may progress in part 
by nuclear factor κB (NFκB) activation via the p38 MAPK pathway66. Studies 
have shown that imatinib may activate p38 MAPK and its downstream molecules, 
MapKapK2 and MSK1 in primary leukemic progenitor cells isolated from CML 
patients67. Recently, it was shown that the phosphorylation of histone 2A family, 
member X (H2AX) is regulated by p38 MAPK and required for the induction of 
apoptosis in K562 cells68. In contrast, Galan-Moya and co-workers reported that 
constitutive active ABL may activate p38 MAPK in an independent mechanism to 
its innate tyrosine kinase activity and, via its ability to stabilize MKK6, an 
upstream activator of p38 MAPK69. Elucidation of the mechanisms involved in the 
interactions between BCR-ABL and p38 MAPK is thus important in order to 
assess its role in disease progression, and therapeutic intervention. 
 
Phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway. The 
PI3K/Akt pathway is well characterized in CML, with its constitutive activation in 
BCR-ABL+ cells observed to possess an important role in cell survival and 
malignant transformation dependent on the BCR-ABL oncogene70,71. Subsequent 
phosphorylation of critical survival proteins by Akt including transcription factor 
regulator glycogen synthase kinase 3β (GSK3β), is important in regulating 
downstream events resulting in a decrease in the susceptibility of cells to 
undergo apoptosis72. Naughton and co-workers reported that elevated ROS 
production (expression of BCR-ABL is associated with increased production of 
intracellular ROS) in cells expressing BCR-ABL was found to activate the 
PI3K/Akt pathway through the ability to regulate important factors and 
downstream effectors including Akt, GSK3β, β-catenin, and Mcl-170. The tumour 
suppressor gene, phosphatase and tensin homologue deleted on chromosome-
10 (PTEN) has also been shown to be down-regulated by BCR-ABL in CML 
progenitor cells, with the deletion accelerating disease development through the 
regulation of the Akt1 gene73. The anti-apoptotic signaling of PI3K/Akt has also 
been shown to contribute to TKI resistance, with the inhibition of PI3K enhancing 
the efficacy of imatinib74. Demonstration of imatinib treatment activating the 
PI3K/Akt pathway in BCR-ABL+ cells and primary leukemia cells in vitro, as well 
as in a chronic phase CML patient in vivo was reported75. It was found that this 
activation was critically important in mediating survival during the early phases of 
resistance acquisition, and was prior to the manifestation of BCR-ABL-dependent 
resistance mechanisms. Similarly, in five Ph+ cell lines observed to be TKI-
resistant despite no underlying mutations or other molecular aberrations 
indicated in conventional resistance, the activation of the PI3K/Akt pathway was 
unaffected following imatinib treatment76. Inhibition of Akt1 however led to 
apoptosis in these cell lines, indicating that select forms of TKI resistance are 
attributable to mechanisms independent of BCR-ABL, including the constitutive 
activation of PI3K/Akt signaling. Most recently, the drug efflux pump, ATP-binding 
cassette sub-family G member 2 (ABCG2) implicated in multidrug resistance 
(MDR), and observed to be upregulated in TKI-resistant K562 cell lines, was 
involved in MDR in CML through the PI3K/Akt signaling pathway, and more 
specifically via PTEN down-regulation77. More specifically, ABCG2 function was 
correlated with drug resistance and disease progression, mediated at least in 
part, by Akt activation. 
 
Focal adhesion signaling pathway. Expression of the BCR-ABL oncoprotein 
has been demonstrated to affect hematopoietic cell adhesion to the bone marrow 
via a number of mechanisms, including the ability to mediate important 
interactions between cellular adhesion receptors and protein components of the 
extracellular matrix (ECM)78.  
 
  
1.5. Leukemic stem cells (Cancer progenitor cells) in CML 
 
Due to the finding that TKI therapy may only induce cell death in proliferating 
mature cells, coupled with the increasing biological evidence for a population of 
malignant cells with self-renewal properties that may initiate cancer development, 
it is suggested that a reservoir of primitive quiescent progenitor cells insensitive 
to TKI treatment is present in residual disease and is responsible for CML 
relapse and progression79,80. Interestingly, incubation of CML stem cells with 
TKIs in vitro led to an increased number of quiescent progenitor cells compared 
to untreated cells80-82. As a rare phenotypically distinct subpopulation of cancer 
cells that are thought to be responsible for tumorigenesis, it is proposed that an 
anticancer therapeutic strategy that targets CML stem-like cells may effectively 
eradicate the disease with a decreased risk of reoccurrence and phase 
advancement. 
 
1.5.1. Biological identification and characterization of CML progenitor cells 
 
The characterization of CML progenitor cells has been difficult with a selective 
method for their isolation not yet established, however a focus on subsets of 
normal and leukemic human hematopoietic (CD34+) cells is of particular interest 
in research to date. The CD34+CD38- /Lin- fraction of the leukemic clone has 
been implicated as an enriched subset which gives rise to such CML stem-like 
cells83,84. They may also be further refined by their aldehyde dehydrogenase 
(ALDH) 1 activity, with high ALDH expression in CML stem-like cells capable of 
engrafting mice compared to more differentiated CML progenitor cells within the 
CD34+/CD38- population85. However, normal hematopoietic stem cells may also 
exhibit this phenotype, which demonstrates a requirement for the identification of 
additional markers that may distinguish CML progenitor cells from the normal 
population86. A number of markers have been described as differentially 
expressed on CML progenitor cells in comparison to normal bone marrow stem 
cells.  
Genome-wide profiling of CML stem-like cell populations via microarray analysis 
resulted in the finding that CML subsets display greater variability in the gene 
expression patterns than their normal counterparts85. Thirty-one transcripts were 
found to be upregulated in CML CD34+/CD38-/ALDHhigh cells in comparison to 
normal CD34+/CD38-/ALDHhigh or CD34+/CD38- cells, including genes in key 
cell signaling and metabolic pathways. 
Functional annotation of the genes highlighted several plasma membrane-
associated genes, with DPP-IV (CD26), IL-2RA (CD25), RAB31, PTPRD, 
CACNA1D, IL-1RAP, SLC4A4, and KCNK5 all upregulated and exhibiting cell 
surface protein localization. Microarray expression levels were further verified by 
qRT-PCR. Expressed on normal myeloid cells as well as on CD34+ blast cells in 
acute myeloid leukemia, the cell surface antigen CD33, has also been shown to 
be expressed at significantly higher levels on stem cell-enriched CD34+/CD38- 
leukemic cells compared to normal CD34+/CD38- stem cells87.  
Samples collected from chronic phase CML patients, CD33 was found to be 
expressed invariably in the majority of cells, in comparison to the highly variable 
levels observed in those stem-like cells from patients with accelerated or blast 
phase disease. The surface antigen CD44 has also been found to be 
upregulated on CML BCR-ABL-expressing leukemic stem-like cells from human 
bone marrow88. Similar results were also observed from bone marrow samples of 
mice with CML-like leukemia, with decreased CD44 levels observed in malignant 
progenitors from the blood or spleen, suggested that CD44 may be involved in 
the retention of BCR-ABL+ stem cells in the bone marrow stroma89. The 
identification of the IL-1 receptor accessory protein (IL-1RAP) as a candidate 
marker of CML has also been widely reported90.  
The adenosine A1 receptor has also been implicated, with differential mRNA 
expression and protein levels observed on CD34+ CML cells compared to their 
normal counterparts91.  
A recent study from Nievergall and co-workers showed that CD123 expression 
was increased in CD34+/CD38- of both chronic-phase and blast-phase CML 
patients92. In addition, IL-3 plasma levels in chronic-phase CML patients was 
seen to be higher at diagnosis relative to plasma samples of healthy donors, and 
reduced in matched samples of patients treated with TKIs. 
Various studies have also displayed an importance of CD117 (c-Kit) expression 
in the identification of CD34+ CML progenitor cells93-95. CD117 is a 
transmembrane receptor with tyrosine kinase activity and is widely expressed in 
CD34+ cells including hematopoietic stem cells and myeloid progenitor cells for 
their physiological development and survival. The proportion of CD34+/CD117+ 
cells is found to be higher in patients with CML in comparison to healthy subjects. 
In CML, it is suggested that the upregulation of CD117 on CD34+ progenitor cells 
is critical in the activation of survival mechanisms independent of BCR-ABL.  
CD25, the α-chain of the IL-2 receptor (IL-2Rα), is a subunit of the high-affinity 
IL-2 receptor and is involved in the transduction of the cytokine to regulate cell 
survival and proliferation. Using a CML-like mouse model of myeloproliferative 
disease, it was demonstrated that CML progenitor cells may be divided into 
CD25+/Lin-/Sca-1+/c-Kit+ (LSK) cells and CD25- LSK cells96. Similar results 
were reported in a study, with CD25 aberrantly and specifically expressed on 
human CD34+/CD38-/Lin- CML progenitor cells in comparison to the finding that 
CD25 was undetectable or weakly expressed on normal hematopoeitic stem 
cells. 
Most recently, the surface enzyme CD26 (DPP-IV) was identified as a specific, 
reliable, and functionally important marker of leukemic stem cells in CML97. 
Results from gene array, PCR and flow cytometry studies found that CD26 was 
invariably expressed on progenitor cells in all CML patient bone marrow, but 
failed to be detected on CD34+/CD38- stem cells in normal samples or on cancer 
stem-like cells in other myeloid malignancies. Furthermore, CD26 was not 
detected on more mature CD34+/CD38+ progenitor cells in CML patients. An 
association between the expression of CD25 and CD26 on CML stem-like cells 
was also observed, with only CD26+ cells found to express the BCR-ABL1 gene 
by FISH and qPCR. Notably, the expression of CD26 was not dependent on 
BCR-ABL1, or inhibited by imatinib treatment. Further study is required in order 
to assess the potential of CD26 as a therapeutic target, although preliminary data 
from this publication is promising.  
 
1.5.2. Molecular pathways involved in the survival and function of CML 
leukemic stem cells 
 
Despite the biological evidence for a CML stem cell population that possesses 
the capacity to sustain disease, the immunophenotypic identification of a 
leukemic stem-like cell remains to be completely elucidated. In fact, CML 
progenitor cells (CD34+ cells) are thought to be similar to normal hematopoietic 
stem cells with self-renewal properties as well as the ability to give rise to a 
heterogeneous population of cells, and only differ by the presence of the bcr-abl 
gene mutation. Interestingly however, is the finding that these CML progenitor 
cells are not dependent on the BCR-ABL oncoprotein for survival98. This is 
perhaps the most important consideration to understanding the factors that 
contribute to the survival of CML stem-like cells and their innate resistance to TKI 
therapy. Therefore, complete elucidation of the mechanisms involved in the 
functional maintenance and survival of CML progenitor cells is required in order 
to determine molecular pathways alternative to BCR-ABL which may be 
therapeutically targeted, ultimately leading to their eradication and/or 
sensitization to TKI treatment.  
 
ALOX5 and lipid metabolism. Important in a number of processes including 
oxidative stress response, lipid metabolism, and synthesis of leukotriene B4, 
arachidonate 5-lipoxygenase (ALOX5) has been shown to be upregulated by 
BCR-ABL in CML stem-like cells99. In addition, administration of TKI failed to 
affect the increase in both gene expression and function of ALOX5, suggesting 
that this upregulation was independent of kinase activity. Chen and co-workers 
further demonstrated that ALOX5 is critical in disease development, with Alox5-
null mice failing to develop CML following implantation of BCR-ABL- transduced 
bone marrow cells. Co-expression of BCR-ABL and Alox5 in mice resulted in 
disease induction, confirming the finding. More specifically, ALOX5 was observed 
to regulate the function of CML stem-like cells exclusively, with a deficiency 
leading to a reduction in the bone marrow affecting differentiation, cell division 
and survival of the CML progenitor cells, while maintaining the function of normal 
hematopoietic stem cells. Furthermore, comparative DNA microarray analysis 
was performed in order to identify the pathways regulated by the Alox5 gene in 
CML stem-like cells implicated the macrophage scavenger receptor (Msr1) as a 
candidate gene, which has been shown to be down-regulated via BCR-ABL and 
restored by an Alox5 deficiency in cells100. The loss of functional Msr1 was 
shown to accelerate CML development in murine recipients of BCR-ABL-
transduced bone marrow cells, as well as enhance CML progenitor cell function 
by inhibiting apoptosis and regulating the cell cycle to increase proliferation. 
Inhibition of ALOX5 function via the selective 5-lipoxygenase (5-LO) inhibitor 
Zileuton, has been demonstrated in a CML murine model99 with promising resuts.  
Due to these findings, clinical trials were initiated in order to evaluate the safety 
of Zileuton in combination with TKIs in CML patients (clinicaltrials.gov). A phase I 
study of the 5-LO inhibitor with imatinib was terminated with no results published 
(NCT01130688), and another involving its combination with dasatinib is currently 
recruiting eligible patients (NCT02047149). 
 
Autophagy. The term autophagy is derived from the Greek words “auto” (self) 
and “phagy” (eating) and was firstly used to describe intracellular vesicles that 
contained degraded cytoplasmic material. Since then, autophagy has been 
characterized as a cell survival pathway that functions to degrade and recycle 
cellular components, such as aged proteins and organelles, that can be re-used 
to generate ATP and essential building blocks during nutrient and/or oxygen 
deprivation to maintain homeostasis101. 
Autophagy has been shown to be induced by various drugs in CML cells, 
including TKI treatment in both CML cell lines and primary stem/progenitor 
(CD34+CD38-) cells102. Specific autophagy inhibition, either with ATG7 or ATG5 
knockdown, or pharmacological inhibition using cloroquine (CQ), resulted in 
enhanced TKI-induced death in CML cell lines and primary CML stem cells. 
These promising results have led to the initiation of clinical trials, where hidroxy-
CQ is being tested in combination with imatinib in imatinib-sensitive patients103. 
The fact that autophagy is induced following BCR-ABL inhibition suggests that 
BCR-ABL down-regulates autophagy. In support of this hypothesis, Altman et 
al.,104 demonstrated that BCR-ABL expressing cells exhibited low basal 
autophagy, but were highly dependent on it. They also showed that autophagy 
inhibition following Atg3 deletion in BCR-ABL expressing cells led to increased 
p53 phosphorylation and accumulation, as well as increased expression of the 
p53 target gene, p21 and the pro-apoptotic Bcl-2 family protein Puma. However, 
it was not clear if autophagy inhibition had any effect on mitochondrial number or 
function that could possibly lead to increased DNA damage, as has been shown 
in normal HSCs105. 
The exact mechanism by which BCR-ABL suppresses autophagy is not entirely 
clear. However, two recent papers have shed some light on this. Firstly, Sheng et 
al., showed that BCR-ABL, through the PI3K/Akt pathway, transcriptionally up-
regulated activating trans-cription factor 5 (ATF5) in a FoxO4 dependent 
manner106 and ATF5 in turn, stimulated mTORC1 transcription, required for 
autophagy inhibition. So this model suggests that BCR-ABL not only activates 
mTORC1 kinase activity, but also leads to increased mTORC1 transcription. The 
authors further showed that imatinib-induced autophagy was dependent on 
inhibition of the PI3K/Akt/mTORC1 pathway, as ectopic expression of 
constitutively active PI3K (PI3KCAE545K) suppressed autophagy induced by 
imatinib. Secondly, Yu et al., showed that imatinib inhibited expression of 
microRNA-30a (mir-30a) in CML cells leading to autophagy induction and up-
regulation of BECLIN1 and ATG5 expression107. Taken together this suggests 
that BCR-ABL expression inhibits autophagy by at least two mechanisms 1) in an 
mTORC1 independent manner by inducing mir-30a expression and 2) in an 
mTORC1 dependent manner by inducing mTORC1 activity/expression. To 
support the involvement of active mTORC1 in autophagy inhibition in CML cells, 
OSI-027, an mTOR inhibitor (inhibits both mTORC1 and mTORC2 complexes) 
has been shown to induce protective autophagy in K562 cells and combination of 
OSI-027 and CQ-mediated autophagy inhibition resulted in increased apoptosis 
compared to OSI-027 alone108. Therefore, autophagy may be a key defensive 
mechanism that provides survival and/or limits the apoptotic responses following 
mTOR inhibition in CML cells and combined use of potent mTOR inhibitors with 
autophagy inhibitors may provide an approach to enhance the effect of single 
drug treatment. In reality, autophagy, a tumor suppressor in normal HSC can be 
exploited therapeutically in CML. 
 
Wnt/β-catenin pathway. Canonical Wnt/β-catenin signaling has been implicated 
in numerous biological processes in embryogenesis, and hematopoiesis. β-
catenin is the critical downstream effector molecule that has an observed role in 
the proliferation and survival of normal hematopoietic stem cells. Specifically, 
mice deficient in β-catenin possessed the capacity to form hematopoietic stem 
cells, but failed in the maintenance of these cells long term109. In CML, the 
aberrant activation of the Wnt pathway is thought to have a critical role in both 
disease progression and CML progenitor cell self-renewal and survival. Elevated 
levels of nuclear β-catenin were detected in the granulocyte-macrophage 
progenitor pool from patients with blast-phase CML and imatinib-resistant CML 
compared with marrow collected from healthy individuals110. Implicated in the 
evolution of CML and progression to the blast phase, BCR-ABL has been 
observed to directly interact with β-catenin to control levels of protein stabilization 
and nuclear signaling in malignant cells111. Cross-talk between β- catenin and 
interferon-regulatory factor 8 (Irf8) as also been shown to affect this progression 
to blast phase CML, with an Irf8 deletion and constitutive β-catenin activation 
resulting in the elevated leukemic potential of BCR-ABL+ CML progenitor cells, 
as well as TKI resistance in the CML murine model112. 
Deletion of β- catenin in established CML however, was shown to synergize with 
imatinib to eliminate CML progenitor cells and to delay disease recurrence 
following discontinuation of TKI treatment in vivo113. 
Pharmacological inhibition of β-catenin via a number of mechanisms in 
combination with imatinib has produced promising results for the effective 
treatment of CML, and eradication of CML progenitor cells. 
 
TGF-β/FOXO/BCL-6 signalling. As previously described, the PI3K/Akt pathway 
is activated in CML cells via BCR-ABL-dependent mechanisms leading to 
enhanced cellular survival and malignant transformation. In addition, activation of 
this pathway leads to the phosphorylation, cytoplasmic retention, and inactivation 
of forkhead O (FOXO) transcription factors. In normal hematopoietic stem cells, 
FOXOs localize in the nucleus for the regulation of cell proliferation with its 
transcriptional activity resulting in cell cycle arrest114. Loss of functional FOXO 
has been observed to result in an aberrant increase in ROS production, an 
increase in the number of stem cells in active cell cycling and eventual population 
exhaustion. In the BCR-ABL transduction/transplantation CML murine model, 
active FOXO3a in CML progenitor cells was shown to possess an important role 
in the maintenance of their self-renewal capacity, with deletion of the 
transcription factor resulting in increased proliferation, and decreased apoptosis 
115(243). In CML CD34+ CML progenitor cells, BCR- ABL expression leads to an 
increase of FOXO3a in the cytoplasm rendering the factor transcriptionally 
inactive. Conversely, induction of FOXO3a in leukemic cell lines inhibits cell cycle 
progression, and induces apoptosis via the activation of tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) and p53116. Full restoration of FOXO 
activity in CML progenitor cells also led to the significant decrease in cyclin D1 
mRNA level, and modulation of key target genes including ATM, p57/CDKN1C 
and BCL-6 which are all required for maintenance of their stem cell-like 
properties117,118. Studies also suggest that FOXOs possess a role in the 
mechanism of action associated with TKI therapy in CML, with imatinib exposure 
in several BCR-ABL-expressing cell lines resulting in FOXO3a activation and cell 
cycle arrest119. Interestingly however, is the finding that activation of FOXOs by 
TKIs is a paradoxical, with signaling also contributing to the protection of CML 
CML progenitor cells. In general, the anti-proliferative activity of TKIs against 
CML CD34+ CML progenitor cells is thought to be mediated by the reactivation of 
FOXO1, 3a, and 4 resulting in quiescence120. 
As an important downstream effector of FOXO, B-cell lymphoma 6 (BCL-6) 
protein has been identified as a critical factor in the survival and self-renewal of 
CML progenitor cells through its ability to mediate the repression of Arf and p53 
117,121.  
Transforming growth factor-β (TGF-β) has also been implicated in the acquisition 
of drug resistance in CML progenitor cells via its ability to inhibit Akt activation 
leading to the release and activation of FOXOs to promote their quiescent 
properties115.  
 
Sonic hedgehog signaling pathway. As a critical pathway active during 
embryogenesis and adult homeostasis, the sonic hedgehog (Shh) pathway is 
important in the modulation of hematopoietic stem cell proliferation and survival 
in both physiological and pathological conditions. Briefly, Shh protein ligands bind 
to Patched (Ptch) leading to the release of the transmembrane protein 
smoothened (Smo), and a subsequent signal transduction cascade resulting in 
the nuclear translocation of Gli transcription factors122. Multiple studies have 
indicated that the aberrant activation of the Shh pathway in CML possesses an 
important role in the regulation of CML progenitor cell survival, as well as in 
disease progression. The significant upregulation of Shh, Smo, and Gli has been 
observed in patients with CML compared with normal controls123. Loss of 
functional Smo in the CML murine model led to an impairment of stem cell 
renewal, a subsequent depletion of these progenitor cells and a subsequent 
decrease in the induction of disease by BCR-ABL124. Conversely, constitutively 
active Smo increased the number of circulating CML progenitor cells thereby 
accelerating disease. In addition, pharmacological inhibition of Shh signalling 
impaired the propagation of BCR-ABL+ CML resistant to imatinib in both murine 
and human studies. 
Furthermore, the upregulation of Shh, Smo and Gli-1 protein expression in blast 
phase CML in comparison to chronic phase disease suggests that the Shh 
signaling pathway is critical in the transformation and progression of human CML 
123. Most recently, upregulation of Smo was associated with reduced expression 
of microRNA-326 in leukemic CD34+ progenitor cells collected from human 
patients with CML at diagnosis compared to healthy controls125.  
Taken together, targeting the Shh pathway and its downstream effector proteins 
may lead to the elimination of disease progenitor cells, with inhibition of Smo or 
Gli-1 of greatest potential in current research settings. 
 
Promyelocytic leukemia protein (PML). The promyelocytic leukemia protein 
(PML), which is critical in normal hemopoiesis, has been shown to regulate 
important processes including apoptosis, proliferation, and senescence in 
hematopoietic stem cells. Deregulation of PML has been observed in CML, with 
increased expression in bone marrow collected from patients with chronic-phase 
disease118. Interestingly, an inverse correlation between PML expression and the 
rates of complete cytogenetic and/or molecular response was determined in 
these patients, suggesting an important association with prognosis. Ito and co-
workers also demonstrated the importance of PML for CML progenitor cell 
maintenance.  
Furthermore, treatment of mice with arsenic trioxide, which induces the 
degradation of PML protein, in combination with chemotherapeutic agent 
cytarabine, led to the down-regulation of PML and an increase in survival. The 
administration of arsenic sulfide in combination with imatinib also displayed 
therapeutic benefit in a BCR-ABL+ murine model126. It was found that while the 
arsenic sulfide targeted BCR-ABL through ubiquination of important lysine 
residues leading to proteasomal degradation, imatinib inhibited the PI3K/Akt 
pathway that ultimately led to cell cycle arrest, decreased tyrosine kinase activity 
and activation of apoptosis in CML progenitor cells. 
 
Interferon signaling (IFN). The role of both IFN-α and IFN-γ in hematopoiesis 
has led to the investigation of their importance in CML. IFN-γ has been shown to 
directly induce the rapid expansion of lineage-Sca-1+c-kit+ (LSK) cells, with IFN-
γ- induced genes important for hematopoietic stem cell survival and maintenance 
127,128. Interestingly, evidence suggests a comparable effect of IFN-γ in CML 
progenitor cells, with the mediator inducing proliferation in leukemia progenitor 
cells as well as in primary CD34+ cells collected from newly diagnosed CML 
patients129. In an in vivo model of CML, accelerated disease progression was 
observed following the secondary transplantation of IFN-γ-treated CML 
progenitor cells suggesting its importance in the expansion of the population.  
IFN-α has been shown to activate quiescent hematopoietic stem cells, mediating 
proliferation130. Prior to the discovery of TKI therapies, IFN-α was the standard 
first-line treatment for CML despite the association with severe adverse effects 
(304). Its mechanism of action involves the capacity to restore adhesion of CML 
progenitor cells to the bone marrow stroma, downregulate the expression of the 
bcr-abl1 gene, and activate several transcription factors that regulate cell 
proliferation, maturation, and apoptosis131-133. IFN-α may also induce recognition 
and elimination of CML cells by the immune system134,135. Most importantly, the 
chronic administration of IFN-α may lead to a depletion in CML progenitor cells, 
via direct and indirect mechanisms involving stromal cells130,136. 
Subsequently, the combination of TKI and IFN-α as a potential treatment 
approach is hypothesized to synergistically eradicate disease through an ability 
to target the CML progenitor cell population in disease. Numerous clinical studies 
have been completed or are in progress to assess the significance of the 
combinatorial therapeutic strategy, with varying results. All the published trials 
reported significant incidence of toxicity, with a discontinuation of high dose 
pegylated IFN-α common during the first year of treatment137,138.  
 
Stromal-derived factor-1 (CXCL12)/ C-X-C chemokine receptor type 4 
(CXCR4) axis. The interaction between the chemokine receptor CXCR4 and its 
ligand CXCL12 is known to be important in early-stage hemopoiesis, and has a 
critical role in normal hematopoietic stem cell migration139. BCR-ABL activity is 
associated with the down-regulation of CXCR4 expression resulting in the 
defective adhesion of CML cells to bone marrow stroma mediating the malignant 
phenotype, and suppressing the CXCL12-induced chemotactic response of CML 
cells140,141. The CXCR4-dependent migration of immature CD34+ CML cells has 
also been shown to be impaired, with the integrin-dependent migration and 
adhesion in response to CXCL12 significantly decreased142. 
It is suggested that CML progenitor cells are protected by the bone marrow 
stroma from imatinib-induced apoptosis, and significantly upregulate the 
expression of the antiapoptotic factor BCL6 in response to TKI therapy143.  
 
Protein phosphatase 2A (PP2A). The inactivation of the tumour suppressor 
protein PP2A has been observed in CML, via the increased expression of SET, a 
nucleus/cytoplasm-localized phosphoprotein which is induced by BCR-ABL in a 
dose- and kinase-dependent manner, progressively increasing during transition 
to blast phase disease144. BCR-ABL may also inactive PP2A by the induction of 
Jak2- and/or src-dependent mechanisms145. The activity of PP2A involves the 
interaction and de-phosphorylation of several factors implicated in the regulation 
of cell cycle progression, proliferation, survival, and differentiation. Interestingly, 
several signaling pathways targeted by PP2A phosphatase are also modulated 
by BCR-ABL, with the expression and/or activity of substrates including myc, 
STAT5, Akt, BAD and Rb known to be essential in leukemogenesis, found to be 
altered in blast phase CML146. The inhibition of SET expression or induced 
expression of PP2Ac in 32D-BCR-ABL cells led to the inhibition of MAPK, STAT5 
and Akt phosphorylation, decreased myc expression, and increased levels of 
pro-apoptotic BAD144.  
Thus, the suppression of PP2A observed in CML progenitor cells may have a 
critical role in the prevention of inactivating mitogenic and survival signals.  
 
Sirtuin-1 (SIRT-1). The upregulation of the nicotinamide adenine dinucleotide 
(NAD+)-dependent protein deacetylase SIRT-1 through the BCR-ABL-dependent 
activation of STAT-5 signalling, has been shown to promote cellular survival, and 
DNA damage repair under oxidative and genotoxic stress147. Yuan and co-
workers detected an upregulation in chronic phase CML CD34+ progenitor cells, 
with a further increase observed in advanced stages. Conversely, normal adult 
hematopoietic stem cells were shown to express low levels of SIRT-1. 
Furthermore, activation of SIRT-1 was associated with the deacetylation of 
multiple substrates, including FOXO1, p53, and Ku70.  
In addition, it is suggested that SIRT-1 possesses an important role in the 
acquisition of TKI-resistant BCR-ABL mutations due to an ability to alter the 
function of DNA repair mechanisms in CML cells, stimulating activity of error-
prone repair following DNA damage148.  
  
2. Rationale of the study 
 
The following considerations have lead the GIMEMA CML WP to design the CML 
0811 trial, a phase III-b study with nilotinib 300 mg BID as first-line treatment of 
chronic-phase CML. 
A) Two independent phase 2 studies reported very high rates of cytogenetic and 
molecular responses in newly diagnosed CML patients treated with nilotinib 400 
mg BID23,149. The GIMEMA CML WP trial 0307 reported a 12-month CCyR, 
MMR, and MR 4.0 rates of 96%, 85%, and 7%, respectively23. A phase 3 
randomized study comparing the efficacy and safety of 300 or 400 mg BID 
nilotinib with imatinib 400 mg daily in early chronic phase CML patients showed 
the superiority of nilotinib25. Nilotinib 300 mg BID is equally effective and better 
tolerated than nilotinib 400 mg BID. Based on these results, nilotinib has been 
registered (FDA and EMA) for the frontline treatment of Ph+ CML at the dose of 
300 mg BID. However, nilotinib-associated atherosclerotic adverse events (AAE) 
were recently uncovered, particularly peripheral arterial occlusive 
disease28,30,31,150,151, raising concerns on the long-term safety of nilotinib. 
Therefore, since it may be possible that nilotinib will be more and more used for 
the first-line treatment of CML, it is important and useful to explore and to assess 
the efficacy and safety of nilotinib in a multicenter, independent study of an 
unselected cohort of patients.  
B) Currently, the most important target of the treatment of CML with TKIs is the 
deep MR, marker of better long-term outcome. Patients with CML on IFN therapy 
that achieve a ratio of BCR-ABL/ABL transcripts of 0.05% or less have an 
excellent long-term prognosis152. Another study published by the MDACC 
reported that achieving a MMR on imatinib correlates with an improved 
probability of a durable cytogenetic remission153. Results from the IRIS study 
suggest that obtaining the MMR after 12 months of imatinib therapy may be a 
marker of stable response. Further on, in the same study, patients with a MMR 
after 12 months of therapy had a significantly better probability of disease-free 
survival compared with those in complete cytogenetic remission, but without a 
MMR154.  
C) Deep MR as been identified as a prerequisite to treatment discontinuation: 
few experiences have been published aimed to evaluate the persistence of the 
MR after imatinib discontinuation. In a pilot study155, 12 patients discontinued 
imatinib after at least 2 years of MR 5.0 (median duration of negativity, 32 
months). Six patients displayed a molecular relapse with a detectable BCR-ABL 
transcript at 1, 1, 2, 3, 4, and 5 months. Imatinib was then reintroduced and led to 
a novel molecular response. Six other patients (50%) still have an undetectable 
level of BCR-ABL transcript after a median follow-up of 18 months (range, 9-24 
months). The results of this pilot trial have been confirmed and extended in a 
second trial, the STIM trial, published in 2010156. One hundred patients were 
enrolled, and 69 patients had at least 12 months follow-up: 42 (61%) of these 69 
patients relapsed (40 before 6 months, one patient at month 7, and one at month 
19). At 12 months, the probability of persistent MR 5.0 for these 69 patients was 
41% (95% CI 29–52). All patients who relapsed responded to reintroduction of 
imatinib. In another study on 80 patients who stopped TKIs after a prolonged 
deep MR (MR 4.5 – 5), 29 patients (36%) lost MMR after a median of 4 months 
off therapy (range, 2 to 17 months); Authors identified the loss of MMR as a safe 
condition for restarting treatment with TKIs.  
Higher rates of deep MR induced by nilotinib compared to imatinib could 
translate in a higher proportion of patients candidate to stopping anti-CML 
treatment, with higher probability of remaining disease-free in the long term. The 
advantages of this possible future scenario could be: first, the chance of 
treatment discontinuation, at least in patients with chronic clinical adverse events; 
second, a potential reduction of the costs of TKI treatment (after the introduction 
of TKI, with the increasing prevalence of CML patients, the costs of CML 
treatment is increasing year by year). 
D) The relapses observed in patients with a stable deep molecular response, 
together with several biologic studies showing the persistence of leukemic stem 
cells in patients with deep molecular response, suggest that targeting the 
leukemic stem cells would be useful for the eradication of the disease. However, 
several mechanisms could be implicated in leukemic stem cells persistence, and 
probably most of them are similar to those that are active in normal stem cells. 
Therefore, the characterization of the leukemic stem cells and the understanding 
of their differences with the normal counterpart are of utmost importance. 
 
Based on these considerations, the aim of the current study is to assess the 
efficacy, mainly in terms of deep MR rates, of nilotinib 300 mg BID treatment in 
newly diagnosed CML-CP patients, in an independent, investigator sponsored 
study. Monitoring of molecular response provides a straightforward opportunity to 
assess patients' response and possible prognosis in the use of targeted therapy. 
The most important endpoint of the present study is the rate of MR 4.0 at 24 
months, which will provide important information to plan and perform future 
studies aimed to discontinue the treatment, either primarily or after addition of 
other drugs targeting residual leukemic stem cells. Translational studies are 
conducted on leukemic stem cells, in order to identify those characteristics that 
may promote the persistence of the disease despite TKI treatment. 
  
3. Methods 
3.1. Objective of the trial 
 
3.1.1. Primary objective 
The primary objective of the CML 0811 trial is to evaluate the efficacy of nilotinib, 
300 mg twice daily with dose increase to 400 mg twice daily in case of 
suboptimal response or failure11 (excluding patients who will fail for progression 
to AP/BP), in a population of patients with Ph-positive, BCR-ABL positive CML in 
early CP. 
 
3.1.2. Secondary Objectives 
• the assessment of the treatment safety; 
• the evaluation of complete cytogenetic response (CCyR) rates and 
kinetics of molecular response; 
• the estimation of the overall survival (OS), the progression-free survival 
(PFS), the failure-free survival (FFS) and the event-free survival (EFS); 
• the characterization of the leukemic stem cells at the proteomic level 
 
3.2. Trial Design 
 
3.2.1 Patient selection criteria 
 
Inclusion Criteria 
• Age ≥ 18 
• Male or female patients with diagnosis of Ph+ and/or BCR-ABL+ CML 
• Early chronic phase (within 6 months from diagnosis) 
• Pretreatment with Hydroxyurea or Anagrelide for a duration of up to 3 
months and/or pretreatment with Imatinib for up to 30 days are permitted 
• Normal serum levels of potassium, magnesium, phosphorus , total calcium 
corrected for serum albumin or phosphorus, or correctable to within 
normal limits with supplements prior to the first dose of study medication 
• Written informed consent prior to any study procedures being performed 
• AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to leukemia 
• Alkaline phosphatase ≤ 2.5 x ULN unless considered due to leukemia 
• Total direct bilirubin ≤ 1.5 x ULN, except know Mb. Gilbert 
• Serum creatinine ≤ 1.5 x ULN 
 
Exclusion criteria 
• Known impaired cardiac function, including any of the following: 
• LVEF < 45% 
• Complete left bundle branch block 
• Right bundle branch block plus left anterior hemiblock, bifascicular block 
• Use of a ventricular-paced pacemaker 
• Congenital long QT syndrome 
• History of or presence of clinically significant ventricular or atrial 
tachyarrhythmias 
• Clinically significant resting bradycardia (<50 beats per minute) 
• QTc>450 msec on screening ECG. If QTc > 450 msec and electrolytes 
are not within normal ranges before Nilotinib dosing, electrolytes should 
be corrected and then the patient rescreened for QTc criterion. 
• Myocardial infarction within 12 months prior to starting study drugs 
• Other clinical significant heart disease (e.g. unstable angina, congestive 
heart failure, uncontrolled hypertension) 
• Serum lipase and amylase > 1.5 x ULN (upper limit of normal) or history of 
acute (i.e., within 1 year of starting study medication) or chronic 
pancreatitis 
• Other concurrent uncontrolled medical conditions (e.g., uncontrolled 
diabetes, active or uncontrolled infections, acute or chronic liver and renal 
disease) that could cause unacceptable safety risks or compromise 
compliance with the protocol 
• Impaired gastrointestinal function or disease that may alter the absorption 
of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and 
diarrhea, malabsorption syndrome, small bowel resection or gastric by-
pass surgery) 
• Concomitant medications with potential QT prolongation (see link for 
complete list: http://www.torsades.org/medical-pros/drug-lists/printable-
drug-list.cfm) 
• Concomitant medications known to interact with CYP450 isoenzymes 
(CYP3A4, CYP2C9, and CYP2C8: see link for complete list 
(http://medicine.iupui.edu/flockhart/table.htm) 
• Patients who have undergone major surgery ≤ 2 weeks prior to starting 
study drug or who have not recovered from side effects of such therapy 
• Patients who are pregnant or breast feeding, or women of reproductive 
potential not employing an effective method of birth control. (Women of 
childbearing potential must have a negative serum pregnancy test within 
48 hours prior to administration of nilotinib). 
• Patients with a history of another primary malignancy that is currently 
clinically significant or currently requires active intervention. 
• Patients unwilling or unable to comply with the protocol. 
 
 
3.2.2. Treatment scheme 
This study is an open-label, multicenter, phase III-b study of nilotinib 
administered orally at the dose of 300 mg twice daily (total daily dose 600 mg 
daily) for 24 months (study core), and indefinitely if it is in the interest of the 
patient. Nilotinib dose is increased to 400 mg BID in case of suboptimal response 
or failure, according to ELN 2009 recommendations, with the exception of 
patients who will fail for progression to AP/BP: in this case the patient will not be 
treated with study drug and the choice of the treatment will be up to the physician 
(Figure 1). 
Study duration is estimated in 6 years, 1 year of estimated enrollment, 2 years 
therapy duration. Thereafter, information is due for other 3 years. 
 
The main data analysis will be performed when all patients will complete 24 
months of treatment (or discontinued earlier). Safety and tolerability profile will be 
assessed by collecting hematologic and non-hematologic adverse events, 
laboratory examinations and ECG data. The molecular response will be 
assessed using the GIMEMA standardized molecular laboratories (Labnet 
network). 
 
Figure 1. Study flow-chart 
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*Complete Response HR (CHR) definition 
- WBC < 10x109/L  
- Platelet count < 450x109/L  
- No immature granulocytes in differential  
- Basophils less than 5%  
- Spleen non palpable  
 
*Hematologic response loss definition 
-the loss of any of the criteria which define CHR 
 
**Definition of failure,  
- No CHR at 3 months  
- No CgR (Ph pos 95%) at 6 months  
- Less than PCgR at 12 months  
- Less than CCgR at 18 months  
- Loss of CHR, any time  
- Loss of CCgR, any time  
- Clonal Chromosomal Abnormalities (CCA) in Ph+ cells.  
- BCR-ABL kinase domain mutations, any time  
 
Nilotinib 300 mg twice 
Response evaluation 
Nilotinib 300 mg twice 
24 months 
maintenance 
Suboptimal 
response*/Failure 
Optimal Response* 
Observation for 
at least 5 years 
Physician’s  
choice 
Nilotinib 
continuation 
No CMR CMR 
End of study 
Nilotinib 
discontinuation 
Nilotinib 400 mg 
twice 3 months 
Progression ABP Failure Optimal/suboptimal 
Response* 
300 mg twice 
Treatment 
monitoring 
committee decision 
Nilotinib 400 mg twice 
3 months 
maintenance 
3.2.3. Primary endpoint 
To assess the deep molecular response (MR 4.0) rate at 24 months of treatment. 
For the purpose of this protocol, MR 4.0 is defined as a BCR-ABL/ABL 
transcripts ratio ≤ 0.01%, or undetectable BCR-ABL transcripts, with quantitative 
RT-PCR in a peripheral blood sample of at least 10 ml, with a at least 10,000 
copies of the control gene ABL14. 
  
3.2.4. Secondary endpoints 
• The toxicity and the compliance to treatment 
• The complete cytogenetic response (CCgR) rate at 3, 6, 12, 18, 24 and 60 
months; 
• The rate and the degree of molecular response at 3, 6, 12, 18, 24 and 60 
months; 
• The time to CCgR, the time to MMR and the time to MR 4.0; 
• Overall Survival (OS), from the date of the first nilotinib dose to death, 
Progression Free Survival (PFS), from the date of the first nilotinib dose to 
progression to AP or BP or death, Failure Free Survival (FFS) from the 
date of the first nilotinib dose to failure or progression or death, Event Free 
Survival (EFS) from the date of the first nilotinib to any event, including 
treatment discontinuation for adverse events, failure, progression to AP or 
BP, or death, whichever comes first. Failure is defined according to ELN 
2013 criteria18. 
 
3.2.5. Therapeutic regimens, expected toxicity, dose modifications 
 
Drug information 
Investigational treatment: nilotinib (AMN107, Tasigna, Novartis Pharma). 
  
Dose and schedule 
 
Patients will be treated with nilotinib: 
- From day 1 onward, 300 mg orally each morning and evening 
approximately 12 hours apart (300 mg BID). 
- In case of suboptimal response or failure (excluding progression to 
AP/BP) and in absence of safety concerns at 300mg BID, the dose is 
increased to 400 BID for 3 months; after 3 months, Nilotinib is continued at 
400 BID in case of optimal or suboptimal response and Nilotinib is 
discontinued in case of failure. 
- After 3 additional months at 400 mg BID, patients still suboptimal may 
continue at the same dose but after agreements with the Treatment 
Monitoring Committee. 
 
Therapy with nilotinib will be continued for up to 24 months, until progression to 
AP/BP or the development of intolerance of treatment. After 24 months of 
treatment, all the patients who at 24 months are in MR 4.0, will be offered to 
continue the study drug free-of-charge until the responsible physician and the 
patient will consider this in the best interest of the patient. For all the patients who 
will not be in MR 4.0 at 24 months, the choice of the treatment will be up to the 
physician. However, all the patients, whether or not in MR 4.0, will be followed-up 
for at least 5 years, and will be offered to participate in subsequent studies of the 
GIMEMA CML WP.  
 
Dose and schedule modifications 
Subjects will be monitored continuously for adverse events (toxicity) while on 
study therapy. This study uses the CTCAE (NCI Common Terminology Criteria 
for Adverse Events) version 4.0 for toxicity and AE reporting. The highest 
reported AE grade should be used to determine the dose modification action. 
 
Dose reduction guidelines for study drugs-related non-haematologic toxicity 
Grade ≥ 2 non-haematologic toxicity must be resolved within 28 days in order to 
resume study drug at the reduced dose. If a grade ≥ 2 non-haematologic toxicity 
does not resolve after 28 days of study drug interruption, the continuation of the 
treatment must be discussed by Local Investigator and Treatment Monitoring 
Committee (TMC) to decide if continuing therapy is in the patient's best interest. 
 
This applies to all clinical AEs, with the exception of cardiac AEs which have 
specific guidelines and to biochemical AEs with the exception of transaminases, 
bilirubin, lipase and amylase for which specific recommendations are made, 
aimed to keep the treatment at the same dose in case of grade 2 AEs. 
 
3.2.6. Clinical evaluation, laboratory tests and follow-up  
A patient can be enrolled within 6 months from diagnosis. Pretreatment with 
Hydroxyurea or Anagrelide for a duration of up to 3 months and/or pretreatment 
with Imatinib for up to 30 days are permitted. Patients can be enrolled only if 
spleen size, peripheral blood percentage of blast cells, eosinophils and 
basophils, and platelet count have been recorded prior to any antileukemic 
treatment, because these data are necessary for assessing the risk.  
 
Before treatment starts 
• Inclusion/exclusion criteria  
• Informed consent  
• Symptoms  
• Physical examination (height, weight, spleen, in cm below costal margin, 
vital signs and other relevant findings, including pulse rate and blood 
pressure)  
• Bone Marrow (BM) aspirate for cytogenetics, qualitative and mutational 
analysis (chromosome banding analysis is mandatory;). A sample must be 
stored for mutational analysis.  
• Blood counts and differential  
• Serum protein concentration and electrophoretic profile, IgG, IgA, IgM 
concentration  
• Serum chemistry (BUN, creatinine, AST, ALT, ALP, GT, bilirubine, 
glycemia,glycated hemoglobin, amylase, lipase, Na, K, Ca, P, Cl and Mg, 
cholesterol, HDL cholesterol, LDL cholesterol, tryglicerides)  
• Pregnancy test  
• Peripheral Blood (PB) for the assessment of BCR-ABL level (RT-Q-PCR). 
Optional if performed at diagnosis.  
• A PB sample for quantitative molecular analysis (RT-Q-PCR) and FISH  
• Peripheral blood for translational studies  
 
Before treatment starts - BASELINE (day 1) 
• Demography  
• Medical history  
• Current medical conditions  
• Prior and concomitant medications  
• Symptoms  
• Physical examination (height, weight, spleen, in cm below costal margin, 
vital signs and other relevant findings, including pulse rate and blood 
pressure)  
• 12-leads ECG and Echocardiogram  
 
During treatment (first 24 months) 
• Physical examination (spleen, in cm below costal margin, vital signs and 
other relevant findings, including body weight, pulse rate and blood 
pressure), is due every 15 day for three months, hence every 3 months.  
• Symptoms and adverse events are recorded continuously  
• Concomitant medications and nilotinib dosing are recorded continuously  
• Blood counts and differential are due at least every 15 days for the first 3 
months, hence at least every month until month 6 and at least every 3 
months thereafter.  
• Serum protein concentration and electrophoretic profile, IgG, IgA, IgM 
concentration are due every 6 months.  
• Serum chemistry is due to every 15 days for 3 months, hence every month 
until month 6 and every 3 months thereafter.  
• A 12 lead ECG is due after 1, 3, 6 and 12 and 24 months.  
• A BM aspirate for cytogenetics (chromosome banding analysis) is due 
after 3, 6, and 12, 18 and 24 months. 
• A PB sample for quantitative molecular analysis (RT-Q-PCR) is collected 
at 3, 6, 9, 12, 15, 18 and 24 months. FISH is optional baseline, due at 3, 6, 
12, 18 and 24 months in case of insufficient n. of metaphases (< 20) for 
BM cytogenetic evaluation  
 
During treatment (from 24 to 60 months) 
The assessment is due for three years and includes: 
• Physical examination every 6 months 
• Symptoms every 6 months 
• Concomitant medications, nilotinib dosing, and adverse events are 
recorded continuously 
• Blood counts and differential every 6 months 
• Serum protein concentration and electrophoretic profile, IgG, IgA, IgM 
concentration every 6 months 
• Serum chemistry every 6 months 
• PB sample for quantitative molecular analysis (RT-Q-PCR) will be 
collected every 3 months. A BM aspirate for cytogenetics (chromosome 
banding analysis) as per clinical practice   
• 12 lead ECG and echocardiogram are due every 12 months  
• Any SAE must be communicated immediately also after the end of study 
core.  
 
End of treatment  
At any time in case of treatment failure or treatment discontinuation:  
• Physical examination (spleen in cm below costal margin, vital signs and 
other relevant findings, including body weight, pulse rate and blood 
pressure)  
• Symptoms and adverse events  
• Concomitant medications and nilotinib dosing.  
• Blood counts and differential  
• Serum protein concentration and electrophoretic profile, IgG, IgA, IgM 
concentration  
• Serum chemistry  
• 12 lead ECG  
• BM aspirate for cytogenetics (chromosome banding analysis) and 
mutational analysis. In case of blast crisis, PB can substitute for BM.  
• PB sample for quantitative molecular analysis (RT-Q-PCR)  
 
3.2.7. Criteria of evaluation  
 
Definition of chronic phase (CP)  
All the following criteria:  
- less than 15% blasts in blood (marrow)  
- less than 30 % blasts + promyelocytes in blood (marrow)  
- less than 20% basophils in blood (marrow)  
- no extrahematologic involvement, apart from spleen and liver  
 
Definition of accelerated phase (AP) 
Any of the following criteria:  
- more than 15% but less than 30% blasts in blood (marrow)  
- more than 30 % but less than 50% blasts + promyelocytes in blood (marrow)  
- more than 20% basophils in blood (marrow)  
 
Definition of blast phase (BP)  
Any of the following criteria:  
- more than 30 % blasts in blood (marrow)  
- more than 50% blasts + promyelocytes in blood (marrow)  
- any extrahematologic involvement, apart from spleen  
 
Definition of risk 
For risk definition, the following criteria are required at diagnosis, prior to any 
treatment:  
- Age  
- Spleen size (cm below costal margin – max distance)  
- Platelet count  
- Blood blasts %  
- Blood eosinophils %  
- Blood basophils %  
 
The risk is calculated according to the international prognostic formulations, 
Sokal157, EURO158, and EUTOS159. 
Definition of failure  
The definition of failure, adapted to the European LeukemiaNet 2013 
recommendations18, includes:  
- No CHR and/or no CgR (Ph+ > 95%) at 3 months  
- Less than PCgR at 6 months and/or BCR-ABL >10% 
- Less than CCgR at 12 months and/or BCR-ABL >1%  
- Loss of CHR, any time  
- Loss of CCgR, any time 
- Confirmed loss of MMR, any time  
- Clonal Chromosomal Abnormalities (CCA) in Ph+ cells, any time.  
- BCR-ABL kinase domain mutations, any time  
 
Complete HR (CHR)  
Complete HR (CHR) is defined by all the following criteria:  
- WBC < 10x109/L  
- Platelet count < 450x109/L  
- No immature granulocytes in differential  
- Basophils less than 5%  
- Spleen non palpable  
- Hematologic response loss is defined by the loss of any of the criteria which 
define CHR  
 
Cytogenetic response 
Conventional Banding Analysis (CBA) is performed on bone marrow cells after 
short term culture (24 and/or 48 hours). The cells are treated with colchicine and 
with hypotonic solution. The pellet is fixed and washed in methanol-acetic acid 
(3:1). The cells are resuspended in fixative and dropped on slides. Karyotypes 
are examined after G-banding or Q-banding. 
The minimum number of metaphases to be scored is 20. 
CBA is performed with the purpose to evaluate: 
- the proportion of Ph pos metaphases 
- the presence of variant translocations 
- the presence of clonal chromosome abnormalities (CCA) in Ph pos cells 
- the presence of clonal chromosome abnormalities (CCA) in Ph neg cells 
All the cytogenetic abnormalities are captured and reported in the e-CRF. 
 
The CgR is defined based on the percentage of Ph pos metaphases, as 
evaluated by chromosome banding analysis of at least 20 marrow cell 
metaphases: 
- Complete (CCgR) if Ph pos 0 
- Partial (PCgR) if Ph pos 1-34% 
- Minor (mCgR) if Ph pos 35-65% 
- Minimal or none (min/none CgR) if Ph pos > 65% 
If only interphase FISH data from PB are available, the response can be defined 
only as non-complete or complete – to be complete by FISH, it is required that 
less than 1% of cells (minimum number 200) have a positive signal. 
 
CgR loss is defined whenever a CCgR is lost to PCgR or less. 
 
Clonal Chromosome Abnormalities (CCA) 
CCA are defined by any chromosome abnormality that becomes detectable in at 
least two cells in two subsequent cytogenetic examinations. 
 
Fluorescence-in-situ-hybridization (FISH) 
FISH analysis of PB cells is required if marrow cells cannot be obtained, at any 
time point. FISH is performed on the cytogenetic pellet of blood cells or marrow, 
using DNA probes that hybridizes to BCR and ABL regions. Only Extra-Signal 
(ES), Dual-Color Dual-Fusion (DCDF) or D-FISH BCR-ABL commercial probes 
can be used. 
 
Molecular Response (MR)  
RT-Q-PCR of BCR-ABL transcripts will be performed with the TaqMan 
technology as previously set up and standardized within the framework of the 
Europe Against Cancer (EAC) program ABL will be used as control gene to 
compensate for differences in RNA quality or RT efficacy, and results will be 
expressed as ratio of BCR-ABL/ABL%.  
The molecular response is assessed on peripheral blood samples using RT-Q-
PCR and is expressed as a ratio between BCR-ABL and ABL:  
 
- Major Molecular Response (MMR) is defined as a BCR-ABL/ABL ratio 
lower than 0.10% (as corrected by lab conversion factor, according to the 
international scale).  
- Deep Molecular Response: 2 different degree and deepness of response 
will be analyzed, the MR 4.0, which defines the primary endpoint and the 
MR 4.5  
- MR 4.0 is defined as an undetectable BCR-ABL transcripts level, or 
detectable BCR-ABL transcripts with BCR-ABL/ABL ratio < 0.01%, with a 
sensitivity of at least 10.000 copies of ABL.  
- MR 4.5 is defined as an undetectable BCR-ABL transcripts level, or 
detectable BCR-ABL transcripts with BCR-ABL/ABL ratio < 0.0032%, with 
a sensitivity of at least 32.000 copies of ABL.  
 
3.2.8. Statistical methods and data analysis 
 
Sample size 
Currently, the most important target of the CML therapy is the deep molecular 
response, a pre-requisite for treatment discontinuation. The aim of the current 
study is to investigate the deep MR rates of nilotinib. The primary endpoint is the 
MR 4.0 rate at 24 months. Sample size estimation has been performed using a 
two-sided binomial test. The MR 4.0 rate at 24 months during imatinib therapy is 
approximately 10%. Establishing that the minimum rate of interest with nilotinib is 
20%, a sample size of 109 patients is required for a 85% power (1-beta) and a 
two-sided type 1 error alfa of 5%. Assuming a 1% of patients with atypical BCR-
ABL transcript (not evaluable for molecular response) and a 10% drop-out rate, 
the total number of patients becomes 122. Patients dropping out early or not 
providing sufficient or missing data for any other reason will be included in the 
analysis set as non-responders. A minimum of 19 patients with MR 4.0 at 24 
months should be observed to define a study success. 
 
Populations for analysis  
This study follows an open-label, single-arm, multi-center design. It is planned 
that the data from all centers that participate in this protocol will be pooled and 
utilized. The main analysis will be performed when the last patient completes the 
24-month visit. ITT analysis set: all patients who received at least one dose of 
study drug. The ITT analysis set will be used for all safety and efficacy analyses.  
 
Statistical analysis  
Patient demographics/baseline characteristics: Qualitative data will be 
summarized by means of contingency tables and quantitative data will be 
summarized by appropriate descriptive statistics.  
Cytogenetic response will be calculated for the Ph positive patients only. Patients 
with atypical transcripts will not be considered for the molecular analysis. The 
cytogenetic and molecular response rates at each time-point will be calculated 
according to the ITT principle (ITT analysis set). Time-to-response is defined as: 
[date of first response - date of first study drug administration +1]. All the time-to-
response variables will be calculated using Kaplan Meier’s product limit 
estimates. The corresponding 95% confidence intervals will be computed as well.  
OS, PFS, FFS and EFS will be calculated from the date of start of treatment until 
death (OS), progression or death (PFS), failure or death (FFS), or any event 
(EFS), whichever comes first. Failure is defined according to ELN 2013 criteria18. 
For overall survival and progression-free survival, follow-up data after the 
discontinuation of the treatment will also be included. All the time to event 
variables will be calculated using Kaplan Meier’s product limit estimates. The 
corresponding 95% confidence intervals will be computed as well. 
The assessment of safety will be based mainly on the frequency of AEs, 
laboratory abnormalities and clinically notable ECG data. All AEs and laboratory 
abnormalities recorded during the study will be summarized by system organ 
class, severity (based on CTC v 4.0 AE grades) and type of AE. The duration of 
exposure to the study medication and total doses taken by the patient will be 
summarized. 
Deaths reportable as SAEs and non-fatal SAEs will be listed by patient and 
tabulated by type of AE. Other safety data (e.g., vital signs, special tests) will be 
considered as appropriate. 
 
3.3. Leukemic Stem cell collection and proteomic analysis 
 
CD34+ cells were purified by immune-magnetic separation from peripheral blood 
(PB) of 7 newly diagnosed chronic phase (CP) CML patients and compared to 
the normal counterpart obtained from normal bone marrow of three healthy 
donors (NBM) and/or from umbilical cord blood (CB) of three donors.  
The phosphorylation status of 40 different proteins belonging to numerous signal-
transduction pathways, and the expression of 31 proteins of the apoptotic 
machinery, were assessed using a customized direct phase proteome profiler 
antibody array. The resulting dots were visualized using ECL and quantified by 
densitometric analysis. 
 
Figure 2. List of proteins and corresponding phosphorylation sites 
detected in the study 
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4. Results 
4.1. Clinical results 
4.1.1. Patients characteristics 
 
One hundred thirty patients were enrolled in 33 Centers in Italy. The median age 
was 50 years (range 18-85); 19% of the patients were ≥ 65 years old; 66% of the 
patients were males. At baseline, 5% of the patients had clonal cytogenetic 
abnormality in the Philadelphia-positive cells (CCA Ph. Variant translocations 
were observed in 7% of the patients. 
The proportion of low risk patients according to Sokal, EURO, and EUTOS 
scores was 43%, 50%, and 92% respectively. The proportion of intermediate risk 
patients according to Sokal and EURO score was 37% and 45%; the proportion 
of patients with high-risk score was 20%, 5%, and 8%, respectively. 
The median follow-up at the cut-off of the present analysis was 24 months (range 
18-36). Patients characteristics are summarized in table 4. 
 
 
Table 4. Patients Characteristics 
 
Patients, n 130 
 
Age, years; median (range) 
65 years or older; n (%) 
Sex male, n (%) 
 
Cytogenetics; n (%) 
CCA Ph+ 
Variant translocations 
 
 
50 (18-85) 
25 (19) 
86 (66) 
 
 
7 (5) 
9 (7) 
 
Relative Risk; n (%) 
! Low 
! Intermediate 
! High 
 
Follow-up, months; median (range) 
Sokal       EURO    EUTOS 
56 (43)      65 (50)    120 (92) 
48 (37)      58 (45)          - 333 
26 (20)        7 (5)         10 (8)3 
 
24 (18-36) 
 
4.1.2 Molecular response 
 
The primary end-point of the trial was the rate of MR 4.0 at 24 months. 
Secondary end-points included the analysis of the rates of MR 4.5. For these 
analyses, the availability of samples with adequate sensitivity is of utmost 
importance. In fact, the definition of the different levels of deep molecular 
response, according to international accepted criteria14, is: 
• MR 4.0: detectable disease ≤ 0.01% BCR-ABL or undetectable disease, with ≥ 
10.000 ABL copies 
• MR 4.5: detectable disease ≤ 0.0032% BCR-ABL or undetectable disease, with ≥ 
32.000 ABL copies 
• MR 5.0: detectable disease ≤ 0.001% BCR-ABL or undetectable disease, with ≥ 
100.000 ABL copies  
 
Considering all the samples with a BCR-ABL/ABL ratio < 0.1% (corresponding to 
MMR), 90% of them had a number of copies of the control gene > 10,000, 
therefore appropriate to define this level of response. More in detail, 52% of the 
samples had a number of ABL copies of 10,001 – 31,999, therefore able to 
define a MR 4.0; 27% had a number of copies of ABL of 32,000 – 99,999, 
therefore enough to define a MR 4.5; 10% of the samples had a number of 
copies > 100,000, therefore able to define a MR 5.0 (Table 5). 
 
 
 
 
Table 5. Sensitivity of molecular samples 
 
 
 
The molecular response at each time point is illustrated in figure 3. The analysis 
is according to the intention-to-treat principle, therefore, not evaluable samples 
are considered as non-responders. 
At 3 months the rates of MMR, MR 4.0, and MR 4.5 were 18%, 3%, and 0%, 
respectively; At 6 months the rates of MMR, MR 4.0, and MR 4.5 were 53%, 
12%, and 2%, respectively; At 12 months the rates of MMR, MR 4.0, and MR 4.5 
were 57%, 28%, and 7%, respectively; At 18 months the rates of MMR, MR 4.0, 
and MR 4.5 were 65%, 29%, and 11%, respectively. 
The median time to major molecular response was 6 months. 
The estimated 24 months rates of MR 4.0 and MR 4.5 were 47% (38 – 57%) and 
22% (16 – 31%) (Figure 4). 
The stability of the molecular response was also analyzed. Sustained MR 4.0 
(4.5.) was defined as MR 4.0 (4.5) for at least 1 year, with at least 3 evaluable 
analyses. Overall, 57/130 (44%) patients achieved a MR 4.0; 27/57 (47%, or 
21% of the total) had a sustained MR 4.0; 30/130 (23%) patients achieved a MR 
4.5; 6/30 (20%, or 5% of the total) had a sustained MR 4.5. 
  
 
  
Number of ABL copies Percentage of samples 
< 10.000 10% 
10.000 - 31.999 (MR4.0) 52% 
32.000 - 99.999 (MR4.5) 27% 
> 100.000 (MR5.0) 10% 
Figure 3. Molecular response at each time-point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Estimated 24 months cumulative rates of MR 4.0.and MR 4.5 
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4.1.3. Response according to ELN 2013 recommendations 
The response at the 3rd month, according to the cytogenetic evaluation, was 
classified as optimal, warning, failure, or not evaluable in 61.5%, 3%, 0.7%, and 
34.6% of the patients, respectively.  According to the molecular evaluation it was 
classified as optimal, warning, or not evaluable in 76.9%, 4.6%, and 18.4% of the 
patients, respectively. 
The response at the 6th month, according to the cytogenetic evaluation, was 
classified as optimal, warning, failure, or not evaluable in 70.8%, 1.5%, 3%, and 
24.6% of the patients, respectively.  According to the molecular evaluation it was 
classified as optimal, warning, failure, or not evaluable in 73.1%, 6.9%, 2.3, and 
18.4% of the patients, respectively. 
The response at the 12th month, according to the cytogenetic evaluation, was 
classified as failure, or not evaluable in 1.5%, and 20.7% of the patients, 
respectively.  According to the molecular evaluation it was classified as optimal, 
warning, failure, or not evaluable in 53.1%, 19.2%, 1.5%, and 25.4% of the 
patients, respectively. 
 
 
Figure 5. Response at different time-points according to ELN 2013 
recommendations 
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Combining the hematologic, cytogenetic, and molecular data (Figure 5), the 
response at the 3rd month was classified as optimal, warning, failure, or not 
evaluable in 82.3%, 6.1%, 0.7%, and 10.7% of the patients, respectively. At the 
6th month, it was classified as optimal, warning, failure, or not evaluable in 80%, 
6.9%, 3.8%, and 9.2% of the patients, respectively. At the 12th month, it was 
classified as optimal, warning, failure, or not evaluable in 53.1%, 18.4%, 2.3%, 
and 25.4% of the patients, respectively. 
 
4.1.4. Events 
Overall, events that lead to permanent nilotinib discontinuation were recorded in 
23 patients (18.4%). Failures according to ELN 2013 criteria were observed in 7 
(5.3%) patients, and progression to accelerated/blast phase in 2 (1.5%) patients. 
At last contact, all patients were alive. 
The estimated 24-months event-free survival (EFS), failure-free survival (FFS), 
progression-free survival (PFS), and overall survival (OS), were 74%, 93%, 98%, 
and 100%, respectively (Figure 6). 
 
Figure 6. Estimated 24-months survival measures 
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4.1.5. Cardiovascular events 
Seven cardiovascular events were observed (Table 6). In 5 cases, they had an 
atherosclerotic pathogenesis: 3 coronary artery diseases and 2 peripheral arterial 
thrombosis. All patients had CV risk factors at baseline. Of note, the total 
cholesterol, and both LDL and HDL cholesterol fractions significantly increased 
during treatment. On the contrary, triglycerides concentrations had not significant 
variations, and neither a significant increase of HbA1c was observed.  
 
Table 6. Cardiovascular adverse events  
 N (%) 
Overall incidence 
 
-  Coronary artery disease 
-  Arterial thrombosis 
-  QTc prolongation 
-  Atrioventricular block 
7/130 (5%) 
 
3 
2 
1 
1 
 
 
4.1.6. Patient disposition 
After a median follow-up of 24 months (range 18-36) all the enrolled patients are 
alive, and 107 (82%) of the patients are still on study (Table 7). The nilotinib daily 
dose was 800 mg, 600 mg, 300 mg or less, in 2%, 75%, and 5% of the patients, 
respectively. The main reason for treatment discontinuation was toxicity (11 
patients, 8%); other reasons included failures (5 patients, 4%), and progression 
to accelerated/blast phase (2 patients, 2%). 
 
Table 7. Patient disposition 
 
 N (%) 
Still on study 
Off-study 
Progression to AP/BP 
Failure 
Toxicity 
Other* 
* Pregnancy, lost follow-up, withdrawal of informed consent 
107 (82) 
23 (18) 
2 (2) 
5 (4) 
11 (8) 
5 (4) 
 
4.2. Biological results 
 
4.2.1 Samples 
 
CD34+ cells were purified by immune-magnetic separation from peripheral blood 
(PB) of 7 newly diagnosed chronic phase (CP) CML patients and compared to 
the normal counterpart obtained from normal bone marrow of three healthy 
donors (NBM) and/or from umbilical cord blood (CB) of three donors.  
CP-CML samples were obtained from patients with WBC counts ranging 
between 41,900 to 421,400; Sokal score resulted intermediate in six patients and 
low in one (Table 8). 
 
Table 8. Characteristics of patients with CD34+ cells collected at diagnosis 
 
 
4.2.2. Analysis of the phospho-proteomic profile 
The comparison between the phospho-proteomic profile of CP-CML CD34+ cells 
and NBM CD34+ cells (Figure 7, 8) showed that the former are characterized by:  
1) lower phosphorylation of STAT2 (p=0.023), STAT5 (p=0.036), and of tyrosine 
kinases of the Src family - Lck, Fyn, Lyn, and Yes (p=0.04) -, involved in the 
regulation of growth and cell survival;  
2) higher phosphorylation of p53, at Ser15 (p=0.047).   
MATERIALS & METHODS 
 
•  CD34+ cells were purified from: 
  peripheral blood (PB) of 7 chronic phase (CP) CML patients, 
  normal bone marrow of 3 healthy donors (NBM), 
  umbilical cord blood (CB) of 3 donors, 
  one leukapheretic product of a normal volunteer (PBSC).  
•  The phosphorylation status of 40 proteins 
from proliferation STP and the expression of 
31 proteins from the apoptotic machinery 
were assessed by using a customized direct 
phase proteome profiler antibody array. The 
resulting dots were visualized using ECL and 
quantified by densitometric analysis.  
Figure 7. Analysis of phospho-proteomic profile reveals that STATs and 
SRK family members resulted differently activated in CML CD34+ cells 
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Figure 8. Detail of STAT2 phospho-proteomic profile  
 
 
 
 
 
 
 
 
 
 
4.2.3 Analysis of the expression of apoptotic proteins 
The analysis of the expression of 32 apoptotic proteins revealed that CD34+ cells 
from CP-CML, compared to normal CD34+ cells (Figure 9, 10), are characterized 
by:  
1) lower expression of the catalase (p=0.044), an enzyme that protects cells from 
the toxic effects of hydrogen peroxide and promotes growth of normal and 
neoplastic cells including myeloid leukemia cells;  
2) higher expression of FADD, a death receptor involved in extrinsic apoptosis 
and necroptosis, and of the heat shock proteins HSP60 and  HSP70, essentials 
for the survival of the cells after toxic stimuli.  
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Figure 9. FADD, HSP60, HSP70 and catalase are differently expressed in 
CML CD34+ cells compared to normal CD34+ cells. 
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Figure 10. Detail of HSP70 expression  
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5. Discussion 
 
Nilotinib is a derivative of imatinib with greater potency and specificity against the 
tyrosine kinase activity of BCR-ABL1, the characteristic leukemogenic protein of 
chronic myeloid leukemia (CML)160. Due to the efficacy shown in imatinib 
resistant or imatinib-intolerant patients, nilotinib has been tested in the first-line 
setting. The randomized phase III trial ENESTnd demonstrated the superior 
efficacy of nilotinib (both at 300 mg and 400 mg twice daily [TD]) compared to 
imatinib 400 mg once daily25. On the basis of this study, Nilotinib was approved 
for the first-line treatment of CML at the dose of 300 mg TD (less toxic and 
equally effective). The latest update, with 5 years of follow-up, confirmed the 
superior anti-leukemic activity of nilotinib, with higher progression-free survival, 
and higher rates of deep molecular responses161. Only other two small phase II 
trials testing prospectively nilotinib frontline (400 mg TD) have been so far 
published by independent investigators (GIMEMA and the MD Anderson)23,149. 
These studies, although with a short follow-up (median less than 18 
months)23,149, showed that nilotinib induced high and fast response rates, with 
few progressions to accelerated-blast phase (AP/BP), and favorable early toxicity 
profile. On the other hand, nilotinib-associated atherosclerotic adverse events 
(AAE) were recently uncovered, particularly peripheral arterial occlusive 
disease28,30,31,150,151, raising concerns on the long-term safety of this drug. 
Since it may be possible that nilotinib will be more and more used for the 1st line 
treatment of CML, this prospective phase III-b trial was performed by the 
GIMEMA CML WP to explore and to assess the efficacy and safety of nilotinib in 
a multicenter, independent study of an unselected cohort of patients. Here, after 
a median follow-up of 24 months, all patients are alive, and only 2 patients have 
progressed to AP/BP. Therefore, our study confirmed that nilotinib is highly 
effective in the prevention of the progression to AP/BP, a condition that today is 
still associated with high mortality rates. 
Failures according to ELN 2013 recommendations were few (7 patients, 5.3%); 
however, about a quarter of patients have discontinued nilotinib treatment by 24 
months, being toxicity the most common reason (11 patients, 8.4%). Despite the 
relatively short follow-up, cardiovascular issues, particularly atherosclerotic 
adverse events (AE), have emerged. The frequency of these AEs may 
counterbalance the anti-leukemic efficacy. Therefore, it seems crucial to identify 
at diagnosis patients at higher risk for atherosclerotic complications during 
nilotinib therapy, evaluating baseline known CV risk factors, promoting the 
improvement of modifiable ones, and, possibly, as recently described162, studying 
biochemical and genetic traits predictive of thrombotic vascular events. 
Importantly, for patients with an unfavorable CV risk profile, other TKIs (i.e. 
imatinib, dasatinib) may be used.  
Currently, one of the most important targets of the treatment of CML with TKIs is 
the achievement of the deep MR, marker of better long-term outcome. Moreover, 
deep MR has been identified as a prerequisite to treatment discontinuation156,163.  
The primary endpoint of the present study is the rate of MR 4.0 at 24 months, 
which can provide important information to plan and perform future studies aimed 
at treatment discontinuation, either primarily or after addition of other drugs 
targeting residual leukemic stem cells.  Here, the estimated 24-month rates of 
MR 4.0 and MR 4.5 were 47% and 22%, respectively. These results compare 
favorably to those obtained with imatinib, in historic cohorts, and confirm the 
findings of the Company-sponsored ENESTnd study164.  
Additional important information derived from the present trial, and not yet 
reported in other nilotinib studies, is the stability of the deep molecular response. 
A stable molecular response for one year or more was maintained by 27/57 
(47%, or 21% of the total) patients that achieved a MR 4.0, and by 6/30 (20%, or 
5% of the total) patients that obtained a MR 4.5, respectively. Considering the 
increasing rates of deep MR over time (MR 4.0: 2%, 12%, 28%, 29% at 3, 6, 12, 
18 months, respectively; MR 4.5: 0%, 2%, 7%, 12% at 3, 6, 12, 18 months, 
respectively), a significant proportion of patients will be candidate to treatment 
discontinuation in the next years, with higher probability of remaining disease-
free in the long term. The advantages of this possible future scenario could be: 
first, the possibility of treatment discontinuation, at least in patients with chronic 
clinical adverse events; second, a potential reduction of the costs of TKI 
treatment (after the introduction of TKI, the costs of CML treatment is increasing 
year by year, with the increasing prevalence of CML patients). 
However, even when a stable deep MR is reached, a significant proportion of 
patients, 40 – 60% depending to the molecular criteria used, will eventually 
relapse156,163. In almost all cases the restarting of the treatment with TKI was able 
to restore a molecular response 
The persistence of detectable disease in most patients, and the clinical relapses 
observed after TKI discontinuation despite a prolonged deep molecular 
response, are mainly related to the persistence of a quiescent population of 
leukemic stem cells. Thus, targeting the leukemic stem cells could be necessary 
for the eradication of the disease. Several mechanisms are implicated in 
leukemic stem cells persistence, and probably most of them are similar to those 
active in normal stem cells. Therefore, the characterization of the leukemic stem 
cells and the understanding of their differences compared to the normal 
counterpart are of utmost importance.  
In our study, patient’s samples were collected at the CML diagnosis, prior to any 
anti-leukemic treatment, to separate the CD34+ stem cells. We focused on their 
proteomic characterization in comparison to CD34+ cells derived from healthy 
donors. The results showed a different phospho-proteomic profile between the 
leukemic and normal CD34+ cells. In particular, in the CD34+ CML cells we 
found: a lower phosphorylation of STAT2, STAT5, and tyrosine kinases of the 
Src family (Lck, Fyn, Lyn, and Yes), involved in the regulation of growth and cell 
survival; a higher phosphorylation of p53.  
The analysis of the expression of proteins involved in the apoptotic machinery 
and in the cell cycle regulation, revealed that CD34+ cells from CP-CML, are 
characterized by lower expression of the catalase, an enzyme that protects cells 
from the toxic effects of hydrogen peroxide and promotes growth of normal and 
neoplastic cells; a higher expression of FADD, a death receptor involved in 
extrinsic apoptosis and necroptosis, and of the heat shock proteins HSP 60 and 
HSP70, essentials for the survival of the cells after various cytotoxic stimuli. 
Taken together, these data show that CD34+ cells from leukemic patients at 
diagnosis, have a proteomic profile that promotes the quiescence through the 
inhibition of proliferation, and that favors cell survival despite cytotoxic stimuli. 
These characteristics may explain, at least partially, why these cells are resistant 
to the treatment with TKIs, which is highly effective in targeting more 
differentiated and proliferating cells, and, ultimately, why these CD34+ cells can 
determine the relapse after treatment discontinuation. 
The presence of these additional and complex changes in the signaling network 
of chronic phase CML must be taken into account for the investigation on novel 
targeted therapies, aimed at the eradication of the disease. 
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